Heterocyclic linker-carrying 1h-benzo [c] [1, 2] thiadiazine-2, 2-dioxides as selective histone deacetylase 6 inhibitors
By developing a selective HDAC6 inhibitor, the problem of non-specific inhibition of HDAC inhibitors in existing technologies has been solved, achieving specific inhibition of the HDAC6 enzyme, reducing side effects, and improving therapeutic efficacy.
Patent Information
- Application Number
- CN202380032928.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-08
- Filing Date
- 2023-02-08
- Publication Date
- 2024-11-15
AI Technical Summary
Existing HDAC inhibitors lack selectivity, resulting in non-specific inhibition of multiple zinc-dependent histone deacetylases, leading to adverse side effects and limiting their application in the treatment of neurological diseases, neurodegenerative diseases, and other conditions.
Develop selective HDAC6 inhibitors, especially compounds containing tetrahydroquinoline moieties, to specifically inhibit the HDAC6 enzyme, reduce inhibition of other HDAC isoenzymes, and lower the risk of genotoxicity.
It achieves specific inhibition of HDAC6 enzyme, reduces side effects, and improves the therapeutic effect in the treatment of cancer, nervous system diseases, inflammation and autoimmune diseases.
Smart Images

Figure BDA0005073471960000041 
Figure BDA0005073471960000061 
Figure BDA0005073471960000081
Abstract
Description
[0001] Related applications
[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 307,932, filed on February 8, 2022, the contents of which are hereby incorporated by reference in their entirety.
[0003] Government Support Statement
[0004] This invention was made with government support under Grant Nos. 5R01NS079183, R41AG058283, and R43HD093464 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Field of the Invention
[0005] The present invention relates to histone deacetylase inhibitors (HDAC6I) that are selective for histone deacetylase 6; pharmaceutical compositions comprising one or more HDAC6Is; methods of increasing the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and / or chemotherapy, the methods comprising contacting cells with one or more HDAC6Is; and methods of treating conditions and diseases in which HDAC6 inhibition provides benefits (e.g., cancer, inflammation, neurological diseases, neurodegenerative disorders, stroke, traumatic brain injury, allogeneic transplant rejection, autoimmune diseases, and malaria), the methods comprising administering to an individual in need thereof a therapeutically effective amount of an HDAC6I of the present invention. Preferentially, the compounds of the present invention can be used to treat peripheral neuropathies, such as Charcot-Marie-Tooth disease and various other neurodegenerative disorders, including Alzheimer's dementia. Background Art
[0006] The histone deacetylase HDAC protein family currently consists of 18 enzymes, which are classified into four subgroups based on their homology to the yeast family. HDAC1, 2, 3 and 8 are classified as class I HDACs based on their homology to yeast Rpd3, which are characterized by ubiquitous expression and localization to the nucleus. Class II HDACs show tissue-specific expression and shuttle between the nucleus and the cytoplasm. These enzymes are homologous to yeast Hda1 and are subdivided into class IIa (HDAC4, 5, 7 and 9) and class IIb (HDAC6 and 10). HDAC11 is the only member of the class IV subfamily and is similar to the catalytic domains of class I and class II enzymes. Class I, class II and class IV HDACs require Zn 2+ Sirtuins 1-7 act as cofactors for deacetylase activity and are also known as conventional HDACs. Their activity is dependent on nicotinamide adenine dinucleotide and they form class III of HDACs.
[0007] HDAC inhibitor drugs have great potential in treating a variety of diseases. In the field of HDAC, there are a large number of HDAC inhibitors (HDACI) compounds that can block deacetylases. Most HDACI compounds inhibit more than one type of HDAC enzyme and are therefore labeled as pan-inhibitors. It turns out that it is challenging to find HDACI compounds that are highly selective for a given subtype (such as HDAC6). So far, only non-selective pan-HDACI compounds (such as and ) have entered the market. However, pan-HDACIs can cause dose-limiting side effects and are therefore limited to use in cancer therapy. Various HDAC isoforms appear to be ideal targets for treating human diseases other than cancer, among which HDAC6 has become a particularly attractive target (Simoes-Pires, C. et al., Mol. Neurodegener. 2013; 8:7). For example, HDAC6I has been shown to potentially treat peripheral neuropathy, such as the major hereditary neuropathy Charcot-Marie-Tooth (CMT) disease (d'Udewalle, C. et al., Nat. Med. 2011, 17(8), 968-74), and Tau protein diseases including Alzheimer's disease (AD) (Selenica, ML et al., Alzheimers Res. Ther. 2014 6(1):12). In addition, since HDAC6 knockout animals can still survive, it is expected that HDAC6I can be safely used to treat non-cancer diseases through long-term administration. HDAC6 is mainly involved in regulating the acetylation state of cytosolic proteins (such as α-tubulin, HSP-90, cortical actin, HSF-1 and other protein targets). This enzyme also plays a role in identifying and clearing polyubiquitinated misfolded proteins in cells through the formation of aggregates. The development of HDAC6 selective compounds was recently reviewed (Kalin, JH et al., J.Med.Chem.2013,56,6297-6313). In general, HDACI contains three main motifs: a zinc binding group (ZBG), a cap group, and a linker bridging the first two ( Figure 1 A properly optimized capping group can improve potency and selectivity, likely through its ability to make appropriate contacts with residues on the enzyme surface.
[0008] Many HDACIs, such as trichostatin A (TSA) and SAHA, contain a hydroxamic acid function as a ZBG ( Figure 1 Many HDAC inhibitors based on hydroxamic acid have been discovered (including the marketed drug ) are genotoxic. Genotoxicity is an undesirable side effect that limits the scope of drugs to diseases that can be considered life-threatening, such as cancer. Of course, for non-cancer diseases that require chronic, long-term administration, the use of HDACI compounds that are not genotoxic will be essential. Therefore, there is an urgent need to discover effective and selective HDACIs, especially HDAC6Is that do not exhibit genotoxic activity.
[0009] A large amount of evidence supports the therapeutic use of HDAC6I in treating a variety of disorders and diseases, including neurodegeneration. However, despite showing overall beneficial effects, such as beneficial neuroprotective effects, the HDAC6I known to date has almost no specificity in HDAC inhibition and may therefore inhibit two or more zinc-dependent histone deacetylases. It is not clear which significant HDACs can confer neuroprotection. Emerging evidence suggests that at least some HDAC isozymes are absolutely necessary for the maintenance and survival of neurons, such as HDAC1. In addition, it has been noted that nonspecific HDAC inhibition also has adverse side effects. Therefore, the current clinical efficacy of nonspecific HDAC6I for stroke, neurodegenerative disorders, nervous system diseases and other diseases and disorders may ultimately be limited. Therefore, it is very important to design, synthesize and test compounds that can act as effective and isozyme-selective HDAC6I, which can improve the effects of nervous system diseases, neurodegenerative disorders, peripheral neuropathy (including chemotherapy-induced neuropathy), traumatic brain injury, cancer, inflammation, malaria, autoimmune diseases and other disorders and diseases mediated by HDAC6.
[0010] An important advance in this area would be the discovery of HDAC6I, particularly selective HDAC6I, which can be used to treat diseases in which HDAC6 inhibition would provide benefit, such as cancer, neurological diseases, traumatic brain injury, neurodegenerative disorders and other peripheral neuropathies, stroke, hypertension, malaria, allograft rejection, rheumatoid arthritis, and various inflammatory conditions. Therefore, there is a great need in the art for effective compounds, compositions, and methods for treating such diseases, either alone or in combination with other therapies for treating these diseases and conditions. The present invention is intended to address this need. Summary of the Invention
[0011] The present invention relates to a histone deacetylase 6 inhibitor (HDAC6I), a pharmaceutical composition comprising HDAC6I, and a method for treating diseases and disorders (e.g., cancer, neurological diseases, mental illnesses, neurodegenerative disorders, peripheral neuropathy, stroke, hypertension, inflammation, traumatic brain injury, rheumatoid arthritis, allogeneic transplant rejection, sepsis, and autoimmune diseases) in which HDAC6 inhibition provides benefits, the method comprising administering a therapeutically effective amount of HDAC6I to an individual in need thereof. The present invention also relates to a method for increasing the sensitivity of cancer cells to radiotherapy and / or chemotherapy. The present invention also allows these HDAC6I to be used in combination with other drugs and / or treatment methods. In some embodiments, the HDAC6I of the present invention exhibits selectivity, particularly relative to certain other HDAC isozymes (e.g., HDAC1). Specifically, the present invention relates to compounds found to contain a tetrahydroquinoline moiety or an analog thereof as a cap residue.
[0012] More specifically, the present invention relates to histone deacetylase 6 inhibitors (HDAC6I) having the general formula I:
[0013]
[0014] or a pharmaceutically acceptable salt and / or solvate thereof, wherein:
[0015] represents a single bond or a double bond; in the case of a five-membered ring moiety, there are two double bonds and three single bonds arranged together to form a five-membered ring heteroaryl;
[0016] X and Y are independently carbon or nitrogen, and Z is N or C(F);
[0017] m=0, 1 or 2; except when R1 is deuterium, m is an integer ranging from 0 to 4;
[0018] If at least one of X and Y is carbon, then n = 0, 1 or 2; or if both X and Y are nitrogen, then n = 0 or 1;
[0019] The sum of o and p is 0 or 1;
[0020] R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, -CH2OH, -CH2CH2OH, cyano, -NR a R b 、-CH2NR a R b 、-C(O)NR a R b 、-S(O)2NR a R b, acetyl, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, F3C-S-, C3-C6 cycloalkyl, (C3-C5 cycloalkyl)-(C1-C3 alkyl)-, (C1-C3 alkyl)-(C3-C5 cycloalkyl)-, (C3-C5 cycloalkyl)-O-, aryl, aryl-O-, aryl-(C1-C 3-membered alkyl)-, aryl-(C1-C3 alkoxy)-, heteroaryl, heteroaryl-O-, heteroaryl-(C1-C3 alkyl)-, heteroaryl-(C1-C3 alkoxy)-, 4- to 6-membered heterocyclyl, or (4- to 6-membered heterocyclyl)-(C1-C3 alkyl)-; or two R1 and / or two R2 are attached to adjacent carbon atoms of their respective aromatic rings and are linked to form a five- or six-membered carbocyclic or heterocyclic ring;
[0021] R a and R b are independently selected from the group consisting of hydrogen and C1-C6 alkyl or C3-C6 cycloalkyl, or these groups may be joined to form a 3- to 7-membered heterocyclic group;
[0022] a in CR for a single key c R d 、C=O、NR e , O or S, or in CR for double bond c or N;
[0023] b in CR for a single key c R d or in CR for double bond c , or b in represents a double bond and a is CR c When is N;
[0024] R c and R d are independently hydrogen, deuterium, fluorine, chlorine, C1-C6 alkyl or C3-C6 cycloalkyl, or they are joined together to form a 3- to 6-membered cycloalkyl;
[0025] R e is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or 4- to 6-membered heterocyclyl;
[0026] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; and
[0027] R fis hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The structures of SAHA and TSA are shown, as well as the general structure of HDAC inhibitors.
[0029] Figure 2A 、 Figure 2B 、 Figure 3A 、 Figure 3B and Figure 4 The biological activities of exemplary compounds disclosed herein are shown.
[0030] Figure 5 An exemplary method for synthesizing compound 51 is shown. DETAILED DESCRIPTION
[0031] Specifically, the present invention is directed to HDAC6I, compositions comprising HDAC6I of the present invention, and therapeutic uses of HDAC6I of Formula I:
[0032]
[0033] or a pharmaceutically acceptable salt and / or solvate thereof, wherein:
[0034] represents a single bond or a double bond; in the case of a five-membered ring moiety, there are two double bonds and three single bonds arranged together to form a five-membered ring heteroaryl;
[0035] X and Y are independently carbon or nitrogen, and Z is N or C(F);
[0036] m=0, 1 or 2; except when R1 is deuterium, m is an integer ranging from 0 to 4;
[0037] If at least one of X and Y is carbon, then n = 0, 1 or 2; or if both X and Y are nitrogen, then n = 0 or 1;
[0038] The sum of o and p is 0 or 1;
[0039] R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, -CH2OH, -CH2CH2OH, cyano, -NR a R b 、-CH2NR a R b 、-C(O)NR a R b 、-S(O)2NR a R b, acetyl, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, F3C-S-, C3-C6 cycloalkyl, (C3-C5 cycloalkyl)-(C1-C3 alkyl)-, (C1-C3 alkyl)-(C3-C5 cycloalkyl)-, (C3-C5 cycloalkyl)-O-, aryl, aryl-O-, aryl-(C1-C 3-membered alkyl)-, aryl-(C1-C3 alkoxy)-, heteroaryl, heteroaryl-O-, heteroaryl-(C1-C3 alkyl)-, heteroaryl-(C1-C3 alkoxy)-, 4- to 6-membered heterocyclyl, or (4- to 6-membered heterocyclyl)-(C1-C3 alkyl)-; or two R1 and / or two R2 are attached to adjacent carbon atoms of their respective aromatic rings and are linked to form a five- or six-membered carbocyclic or heterocyclic ring;
[0040] R a and R b are independently selected from the group consisting of hydrogen and C1-C6 alkyl or C3-C6 cycloalkyl, or these groups may be joined to form a 3- to 7-membered heterocyclic group;
[0041] a in CR for a single key c R d 、C=O、NR e , O or S, or in CR for double bond c or N;
[0042] b in CR for a single key c R d or in CR for double bond c , or b in represents a double bond and a is CR c When is N;
[0043] R c and R d are independently hydrogen, deuterium, fluorine, chlorine, C1-C6 alkyl or C3-C6 cycloalkyl, or they are joined together to form a 3- to 6-membered cycloalkyl;
[0044] R e is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or 4- to 6-membered heterocyclyl;
[0045] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; and
[0046] R fis hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano.
[0047] In one embodiment, the present invention comprises HDAC6I of Formula Ib
[0048]
[0049] wherein R1 and R2 are as defined in Formula I.
[0050] In another embodiment, the present invention comprises HDAC6I of Formula Ib, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0051] Another embodiment comprises HDAC6I of Formula Ic
[0052]
[0053] wherein R1 and R2 are as defined in Formula I.
[0054] In another embodiment, the present invention comprises HDAC6I of Formula Ic, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0055] In another embodiment, the present invention comprises HDAC6I of Formula Id
[0056]
[0057] wherein R1 and R2 are as defined in Formula I.
[0058] In another embodiment, the present invention comprises HDAC6I of Formula Id, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0059] In another embodiment, the present invention comprises HDAC6I of Formula Ie
[0060]
[0061] wherein R1 and R2 are as defined in Formula I.
[0062] In another embodiment, the present invention comprises HDAC6I of Formula Ie, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0063] In another embodiment, the present invention comprises HDAC6I of formula If
[0064]
[0065] wherein R1 and R2 are as defined in Formula I.
[0066] In another embodiment, the present invention comprises HDAC6I of formula If, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0067] In another embodiment, the present invention comprises HDAC6I of formula Ig
[0068]
[0069] wherein R1 and R2 are as defined in Formula I.
[0070] In another embodiment, the present invention comprises HDAC6I of Formula Ig, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0071] In another embodiment, the present invention comprises HDAC6I of Formula Ih
[0072]
[0073] wherein R1 and R2 are as defined in Formula I.
[0074] In another embodiment, the present invention comprises HDAC6I of formula Ih, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0075] In another embodiment, the present invention comprises HDAC6I of Formula Ii
[0076]
[0077] wherein R1 and R2 are as defined in Formula I.
[0078] In another embodiment, the present invention comprises HDAC6I of formula Ii, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0079] In another embodiment, the present invention comprises HDAC6I of Formula Ij
[0080]
[0081] wherein R1 and R2 are as defined in Formula I.
[0082] In another embodiment, the present invention comprises HDAC6I of formula Ij, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0083] In another embodiment, the present invention comprises HDAC6I of Formula Ik
[0084]
[0085] wherein R1 and R2 are as defined in Formula I.
[0086] In another embodiment, the present invention comprises HDAC6I of formula Ik, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0087] In another embodiment, the present invention comprises HDAC6I of formula IL
[0088]
[0089] wherein R1 and R2 are as defined in Formula I.
[0090] In another embodiment, the present invention comprises HDAC6I of formula IL, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0091] In another embodiment, the present invention comprises HDAC6I of Formula Im
[0092]
[0093] wherein R1 and R2 are as defined in Formula I.
[0094] In another embodiment, the present invention comprises HDAC6I of Formula Im, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0095] In another embodiment, the present invention comprises an HDAC6I of formula
[0096]
[0097] wherein R1 and R2 are as defined in claim 1, and both R3 are methyl, or one R3 is methyl and the other is H, or both R3 together are CH2CH2 or CH2CH2CH2.
[0098] In another embodiment, the present invention comprises HDAC6I of formula In, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0099] In another embodiment, the present invention comprises an HDAC6I of Formula Io
[0100]
[0101] wherein R1 and R2 are as defined in claim 1, and both R3 are methyl, or one R3 is methyl and the other is H, or both R3 together are CH2CH2 or CH2CH2CH2.
[0102] In another embodiment, the present invention comprises HDAC6I of formula Io, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0103] In another embodiment, the present invention comprises HDAC6I of formula Ip
[0104]
[0105] wherein R1 and R2 are as defined in Formula I.
[0106] In another embodiment, the present invention comprises HDAC6I of Formula Ip, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0107] In another embodiment, the present invention comprises HDAC6I of Formula Iq
[0108]
[0109] wherein R1 and R2 are as defined in Formula I.
[0110] In another embodiment, the present invention comprises HDAC6I of formula Iq, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0111] In another embodiment, the present invention comprises HDAC6I of Formula Ir
[0112]
[0113] wherein R1 and R2 are as defined in Formula I.
[0114] In another embodiment, the present invention comprises HDAC6I of formula Ir, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0115] In another embodiment, the present invention comprises HDAC6I of Formula Is
[0116]
[0117] wherein R1 and R2 are as defined in Formula I.
[0118] In another embodiment, the present invention comprises HDAC6I of Formula Is, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0119] In another embodiment, the present invention comprises HDAC6I of formula It
[0120]
[0121] wherein R1 and R2 are as defined in Formula I.
[0122] In another embodiment, the present invention comprises HDAC6I of formula It, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0123] In another embodiment, the present invention comprises HDAC6I of formula Iu
[0124]
[0125] wherein R1 and R2 are as defined in Formula I.
[0126] In another embodiment, the present invention comprises HDAC6I of formula Iu, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0127] In another embodiment, the present invention comprises HDAC6I of Formula Iv
[0128]
[0129] wherein R1 and R2 are as defined in Formula I.
[0130] In another embodiment, the present invention comprises HDAC6I of Formula Iv, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0131] In another embodiment, the present invention comprises HDAC6I of Formula Iw
[0132]
[0133] wherein R1 and R2 are as defined in Formula I.
[0134] In another embodiment, the present invention comprises HDAC6I of formula Iw, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0135] In another embodiment, the present invention comprises an HDAC6I of Formula Ix
[0136]
[0137] wherein R1 and R2 are as defined in claim 1, and both R3 are methyl, or one R3 is methyl and the other is H, or both R3 together are CH2CH2 or CH2CH2CH2.
[0138] In another embodiment, the present invention comprises HDAC6I of Formula Ix, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0139] In another embodiment, the present invention comprises HDAC6I of Formula Iy
[0140]
[0141] wherein R1 and R2 are as defined in claim 1, and both R3 are methyl, or one R3 is methyl and the other is H, or both R3 together are CH2CH2 or CH2CH2CH2.
[0142] In another embodiment, the present invention comprises HDAC6I of formula Iy, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0143] In another embodiment, the present invention comprises HDAC6I of Formula Iz
[0144]
[0145] wherein R1 and R2 are as defined in Formula I.
[0146] In another embodiment, the present invention comprises HDAC6I of formula Iz, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0147] In another embodiment, the present invention comprises HDAC6I of Formula Iaa
[0148]
[0149] wherein R1 and R2 are as defined in Formula I.
[0150] In another embodiment, the present invention comprises HDAC6I of formula Iaa, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0151] In another embodiment, the present invention comprises HDAC6I of Formula Ibb
[0152]
[0153] wherein R1 and R2 are as defined in Formula I.
[0154] In another embodiment, the present invention comprises HDAC6I of formula Ibb, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0155] In another embodiment, the present invention comprises HDAC6I of Formula Icc
[0156]
[0157] wherein R1 and R2 are as defined in Formula I.
[0158] In another embodiment, the present invention comprises HDAC6I of formula Icc, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0159] In another embodiment, the present invention comprises HDAC6I of formula Idd
[0160]
[0161] wherein R1 and R2 are as defined in Formula I.
[0162] In another embodiment, the present invention comprises HDAC6I of formula Idd, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0163] In another embodiment, the present invention comprises HDAC6I of formula lee
[0164]
[0165] wherein R1 and R2 are as defined in Formula I.
[0166] In another embodiment, the present invention comprises HDAC6I of formula lee, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0167] In another embodiment, the present invention comprises HDAC6I of Formula Iff
[0168]
[0169] wherein R1 and R2 are as defined in Formula I.
[0170] In another embodiment, the present invention comprises HDAC6I of Formula Iff, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0171] In another embodiment, the present invention comprises HDAC6I of formula IgG
[0172]
[0173] wherein R1 and R2 are as defined in Formula I.
[0174] In another embodiment, the present invention comprises HDAC6I of formula lgG, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0175] In another embodiment, the present invention comprises an HDAC6I of formula Ihh
[0176]
[0177] wherein R1 and R2 are as defined in claim 1, and both R3 are methyl, or one R3 is methyl and the other is H, or both R3 together are CH2CH2 or CH2CH2CH2.
[0178] In another embodiment, the present invention comprises HDAC6I of formula Ihh, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0179] In another embodiment, the present invention comprises HDAC6I of Formula Iii
[0180]
[0181] wherein R1 and R2 are as defined in claim 1, and both R3 are methyl, or one R3 is methyl and the other is H, or both R3 together are CH2CH2 or CH2CH2CH2.
[0182] In another embodiment, the present invention comprises HDAC6I of formula Iii, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0183] In another embodiment, the present invention comprises HDAC6I of formula Ijj
[0184]
[0185] wherein R1 and R2 are as defined in Formula I.
[0186] In another embodiment, the present invention comprises HDAC6I of formula Ijj, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0187] In another embodiment, the present invention comprises an HDAC6I of formula Ikk
[0188]
[0189] wherein R1 and R2 are as defined in Formula I.
[0190] In another embodiment, the present invention comprises HDAC6I of formula Ikk, wherein R1 and R2 are independently selected from H, D, Cl and F.
[0191] In another embodiment, the present invention comprises an HDAC6I of formula
[0192]
[0193] in
[0194] represents a single bond or a double bond; of the five bonds so labeled, two are double bonds and three are single bonds, which are arranged together to form a five-membered ring heteroaryl group;
[0195] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f), one of d and e is oxygen, and the other is nitrogen;
[0196] R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano;
[0197] and R1 and R2 are as defined in Formula I.
[0198] In another embodiment, the present invention comprises HDAC6I of formula ILL, wherein R1 and R2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
[0199] In another embodiment, the present invention comprises HDAC6I of Formula Imm
[0200]
[0201] in
[0202] represents a single bond or a double bond; of the five bonds so labeled, two are double bonds and three are single bonds, which are arranged together to form a five-membered ring heteroaryl group;
[0203] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen;
[0204] R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano;
[0205] and R1 and R2 are as defined in Formula I.
[0206] In another embodiment, the present invention comprises HDAC6I of formula Imm, wherein R1 and R2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
[0207] In another embodiment, the present invention comprises an HDAC6I of formula
[0208]
[0209] in
[0210] represents a single bond or a double bond; of the five bonds so labeled, two are double bonds and three are single bonds, which are arranged together to form a five-membered ring heteroaryl group;
[0211] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen;
[0212] R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano;
[0213] and R1 and R2 are as defined in Formula I.
[0214] In another embodiment, the present invention comprises HDAC6I of formula Inn, wherein R1 and R2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
[0215] In another embodiment, the present invention comprises HDAC6I of formula loo
[0216]
[0217] in
[0218] represents a single bond or a double bond; of the five bonds so labeled, two are double bonds and three are single bonds, which are arranged together to form a five-membered ring heteroaryl group;
[0219] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen;
[0220] R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano;
[0221] and R1 and R2 are as defined in Formula I.
[0222] In another embodiment, the present invention comprises HDAC6I of formula loo, wherein R1 and R2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
[0223] In another embodiment, the present invention comprises an HDAC6I of formula Ipp
[0224]
[0225] in
[0226] represents a single bond or a double bond; of the five bonds so labeled, two are double bonds and three are single bonds, which are arranged together to form a five-membered ring heteroaryl group;
[0227] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen;
[0228] R fis hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano;
[0229] and R1 and R2 are as defined in Formula I.
[0230] In another embodiment, the present invention comprises HDAC6I of formula Ipp, wherein R1 and R2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
[0231] In another embodiment, the present invention comprises an HDAC6I of formula Iqq
[0232]
[0233] in
[0234] represents a single bond or a double bond; of the five bonds so labeled, two are double bonds and three are single bonds, which are arranged together to form a five-membered ring heteroaryl group;
[0235] One of c, d and e is oxygen, and the rest are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen;
[0236] R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano; and
[0237] R1 and R2 are as defined in Formula I.
[0238] In another embodiment, the present invention comprises a compound listed in Table 1. Table 1. Containing 1H-benzo[c] Example of HDAC6I with [1,2]thiazine-2,2-dioxide or related moieties as capping groups. a
[0239]
[0240]
[0241]
[0242]
[0243]
[0244]
[0245]
[0246] In addition, salts, prodrugs, hydrates, isotope-labeled and fluorescently labeled derivatives of HDAC6I of the present invention, as well as any other therapeutically or diagnostically relevant derivatives, are also included in the present invention and can be used in the methods disclosed herein. The present invention also includes all possible stereoisomers and geometric isomers of the compounds of the present invention. The present invention includes racemic compounds and optically active isomers. When the HDAC6I of the present invention is required to be a single enantiomer, it can be obtained by resolving the final product or by stereospecific synthesis from isomerically pure starting materials or using chiral auxiliary reagents, for example, see Ma, Z. et al., Tetrahedron: Asymmetry, 1997, 8, 883-888. The resolution of the final product, intermediate or starting material can be achieved by any suitable method known in the art. In addition, in the case where the compounds of the present invention may exist as tautomers, the present invention is intended to include all tautomeric forms of the compound.
[0247] Deuterium-labeled compounds of the present invention are of interest because CD bonds are observed to be less susceptible to cleavage than C-H bonds, and therefore metabolic degradation involving attacks on these bonds is slowed after H is replaced by D, resulting in an increase in the half-life of the drug substance (see, for example, Halford, B. Chem. Eng. News 2016, 94(27), 32-36). Preferred C-H bonds to be replaced by CD bonds are aliphatic C-H bonds adjacent to an amine nitrogen atom; aliphatic C-H bonds adjacent to an oxygen atom of an alkoxy substituent; and aromatic C-H bonds, which may be replaced in whole or in part by CD bonds.
[0248] Lactams and amides can be reduced to deuterated amines containing the CD2 moiety adjacent to their amine nitrogen atom. Commercially available deuterated reducing agents, such as LiAlD4 and BD3-THF, are commonly used to reduce these to amines. Alternatively, alkylation of the nitrogen atom with a deuterated alkyl group can be achieved by treatment with the corresponding deuterated alkyl halide in the presence of a base, or by reductive alkylation with the corresponding deuterated aldehyde (containing the C(D)O moiety) using, for example, AcOD containing NaBD(OAc)3 as a reducing agent. When a methoxy substituent is present on an aromatic ring of a compound of the invention, its trideuterated methoxy analog can be obtained by alkylation of the corresponding phenol with CD3I or (CD3)2SO4 in the presence of a suitable base, such as K2CO3 or NaH. Similarly, alkylation of the same phenol with RCD2Br or RCD2I and a base produces a 1,1-dideuterated alkyl ether. Compounds containing deuterium as a substituent on one or more aromatic rings can be synthesized from perdeuterated starting materials or by selectively installing deuterium atoms by reducing aryl bromides or aryl iodides with tri-n-butyltin deuteride in the presence of a transition metal catalyst (e.g., a palladium compound).
[0249] The present invention also includes prodrugs of the compounds of the present invention. It has been well established that the prodrug approach has been successfully used to temporarily (e.g., bioreversibly) alter the physicochemical properties of a compound, wherein the compound is derivatized into a form suitable for formulation and / or administration and then released as a drug in vivo (see H. Bundgaard, ed., "Design of Prodrugs," Elsevier, Amsterdam, (1985); RB Silverman, "The Organic Chemistry of Drug Design and Drug Action," Academic Press, San Diego, Chapter 8, (1992); KM Hillgren et al., Med. Res. Rev., 15, 83 (1995)).
[0250] The compounds of the present invention may exist in salt form. In the methods of the present invention, pharmaceutically acceptable salts of HDAC6I of the present invention are generally preferred. As used herein, the term "pharmaceutically acceptable salt" refers to a salt or zwitterionic form of a compound of the present invention. Salts of the compounds of the present invention can be prepared during the final isolation and purification of the compound, or prepared separately by reacting the compound with an acid having a suitable anion. Pharmaceutically acceptable salts of the compounds of the present invention may be acid addition salts formed with a pharmaceutically acceptable acid. Examples of acids that can be used to form pharmaceutically acceptable salts include inorganic acids such as nitric acid, boric acid, hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; and organic acids such as oxalic acid, maleic acid, succinic acid, tartaric acid, and citric acid. Examples of salts of the compounds of the present invention include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, 2-hydroxyethanesulfonate, phosphate, hydrogenphosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, mesitylenesulfonate, 1-naphthalenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, undecanoate, lactate, citrate, tartrate, gluconate, ethanedisulfonate, benzenesulfonate, and p-toluenesulfonate. In addition, available amino groups present in the compounds of the present invention may be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. In view of the foregoing, any reference to a compound of the present invention herein is intended to include the compound of the present invention and a pharmaceutically acceptable salt, hydrate, or prodrug thereof.
[0251] The compounds of the present invention can also be conjugated or connected to an auxiliary part to promote the beneficial properties of the compound in the therapeutic use method. Such conjugates can enhance the delivery of the compound to the specific anatomical site or region (e.g., tumor) of interest, enabling the compound to maintain therapeutic concentrations in target cells, changing the pharmacokinetic and pharmacodynamic properties of the compound, and / or improving the therapeutic index or safety profile of the compound. Suitable auxiliary parts include, for example, amino acids, oligopeptides or polypeptides, such as antibodies, such as monoclonal antibodies and other engineered antibodies; and natural or synthetic ligands of receptors in target cells or tissues. Other suitable adjuvants include fatty acids or lipid moieties that promote the biodistribution of the compound and / or absorption by target cells (see, for example, Bradley et al., Clin. Cancer Res. (2001) 7: 3229).
[0252] The compounds of the present invention inhibit HDAC6 and can be used to treat a variety of diseases and conditions. Specifically, the HDAC6I of the present invention is used in methods for treating diseases or conditions in which HDAC6 inhibition would provide benefits (e.g., cancer, neurological diseases, neurodegenerative diseases, peripheral neuropathy, autoimmune diseases, inflammatory diseases and conditions, stroke, hypertension, traumatic brain injury, autism, and malaria). The method comprises administering a therapeutically effective amount of the HDAC6I of the present invention to an individual in need thereof.
[0253] In addition to the HDAC6I of the present invention, the methods of the present invention further comprise administering to the individual a second therapeutic agent selected from agents known to be useful in treating the disease or condition afflicting the individual, such as drugs and adjuvants, such as chemotherapeutic agents and / or radiation known to be useful in treating specific cancers.
[0254] The activity of the compounds of the present invention at HDAC6 and their selectivity for HDAC6 compared to other HDACs have been evaluated. Previous studies have shown that selective HDAC6 inhibitors can be used for a variety of disease states, including but not limited to arthritis, autoimmune disorders, inflammatory disorders, cancer, neurological diseases (such as Rett syndrome), peripheral neuropathy (such as CMT), stroke, hypertension, and diseases in which oxidative stress is a causative factor or result. Studies have also shown that selective HDAC6 inhibitors extend the lifespan of mice with renal xenografts when administered in combination with rapamycin. This model is used to evaluate the immunosuppressive properties of the compounds of the present invention and is used as a model for transplant rejection. In addition, previous studies have also shown that selective HDAC6 inhibitors confer neuroprotection in a rat primary cortical neuron model of oxidative stress. These studies have determined that selective HDAC6 inhibitors are non-toxic neuroprotectants. The behavior of the compounds of the present invention is similar because they are also selective HDAC6 agents. The compounds of the present invention exhibit ligand efficiency, making their physicochemical properties more like drugs. Therefore, the compounds of the present invention are drug candidates and research tools for identifying the specific functions of HDAC6.
[0255] Thus, in one embodiment, the invention relates to a method of treating an individual suffering from a disease or condition in which HDAC6 inhibition would provide a benefit, the method comprising administering to the individual in need thereof a therapeutically effective amount of a claimed HDAC6I compound.
[0256] The methods of the present invention can be achieved by administering an HDAC6I of the present invention in the form of a pure compound or in the form of a pharmaceutical composition. Administration of the pharmaceutical composition or pure HDAC6I of the present invention can be performed during or after the onset of the disease or condition of interest. Typically, the pharmaceutical composition is sterile and does not contain toxic, carcinogenic, or mutagenic compounds that would cause adverse reactions upon administration.
[0257] In some embodiments, the HDAC6I of the present invention can be administered in combination with a second therapeutic agent, which can be used to treat a disease or condition for which HDAC6 inhibition provides a benefit. The second therapeutic agent is different from the HDAC6I of the present invention. The HDAC6I of the present invention and the second therapeutic agent can be administered simultaneously or sequentially. In addition, the HDAC6I of the present invention and the second therapeutic agent can be administered by a single composition or two separate compositions. The HDAC6I of the present invention and the second therapeutic agent can be administered simultaneously or sequentially to achieve the desired effect.
[0258] The second therapeutic agent is administered in an amount that provides its desired therapeutic effect.The effective dosage range for each second therapeutic agent is known in the art, and the second therapeutic agent is administered to an individual in need thereof within such determined range.
[0259] Thus, the present invention is directed to compositions and methods of using such compounds to treat diseases or conditions for which HDAC6 inhibition would provide a benefit. The present invention is also directed to pharmaceutical compositions comprising an HDAC6I of the present invention and optionally a second therapeutic agent useful for treating diseases or conditions for which HDAC6 inhibition would provide a benefit. Also provided are kits comprising an HDAC6I of the present invention and optionally a second therapeutic agent useful for treating diseases or conditions for which HDAC6 inhibition would provide a benefit, packaged separately or together, and an insert with instructions for use of the active agents.
[0260] The HDAC6I of the present invention and the second therapeutic agent can be administered together as a single unit dose, or separately as multiple unit doses, wherein the HDAC6I of the present invention is administered before the second therapeutic agent, or vice versa. One or more doses of the HDAC6I of the present invention and / or one or more doses of the second therapeutic agent can be administered. Therefore, the HDAC6I of the present invention can be used in combination with one or more second therapeutic agents (for example, but not limited to, anticancer agents).
[0261] Within the meaning of the present invention, the term "disease" or "disorder" refers to a disorder and / or abnormality that is generally considered a pathological condition or function and can manifest itself in the form of specific signs, symptoms and / or functional impairments. As shown below, HDAC6I of the present invention is a potent inhibitor of HDAC6 and can be used to treat diseases and disorders in which HDAC6 inhibition would provide a benefit, such as cancer, neurological diseases, neurodegenerative diseases, traumatic brain injury, stroke, inflammation, autoimmune diseases and autism.
[0262] In one embodiment, the present invention provides a method for treating cancer, including but not limited to killing cancer cells or neoplastic cells; inhibiting the growth of cancer cells or neoplastic cells; inhibiting the replication of cancer cells or neoplastic cells; or improving its symptoms, the method comprising administering to a subject in need thereof an amount of HDAC6I of the present invention or a pharmaceutically acceptable salt thereof sufficient to treat cancer. In addition, it should be noted that selective HDAC6I may be able to promote killing cancer cells by reactivating the immune system through a mechanism associated with the PDI receptor. The HDAC6I of the present invention can be used as a sole anticancer agent or in combination with another anticancer treatment (e.g., radiation, chemotherapy, and surgery).
[0263] In another embodiment, the present invention provides a method for increasing the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and / or chemotherapy, the method comprising contacting the cells with an HDAC6I of the present invention or a pharmaceutically acceptable salt thereof in an amount sufficient to increase the sensitivity of the cells to the cytotoxic effects of radiotherapy and / or chemotherapy. Thus, the HDAC6I of the present invention can be combined with antibodies against PD-1 and / or PD-L1 to achieve higher efficacy.
[0264] In another embodiment, the present invention provides a method for treating cancer, comprising: (a) administering to an individual in need thereof an amount of an HDAC6I compound of the present invention; and (b) administering to the individual an amount of radiotherapy, chemotherapy, or both. The amounts administered are each effective to treat the cancer. In another embodiment, the amounts are effective together to treat the cancer.
[0265] This combination therapy of the present invention can be used to treat various cancers accordingly in a variety of environments. In a specific embodiment, the individual in need of treatment has previously received cancer treatment. Such previous treatments include but are not limited to previous chemotherapy, radiotherapy, surgery or immunotherapy (such as cancer vaccines).
[0266] In another embodiment, the cancer being treated is one that has been shown to be sensitive to or known to respond to radiation therapy and / or chemotherapy. Such cancers include, but are not limited to, non-Hodgkin's lymphoma, Hodgkin's disease, Ewing's sarcoma, testicular cancer, prostate cancer, ovarian cancer, bladder cancer, laryngeal cancer, cervical cancer, nasopharyngeal cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, esophageal cancer, rectal cancer, small cell lung cancer, non-small cell lung cancer, brain tumors or other CNS neoplasms.
[0267] In another embodiment, the cancer being treated has been shown to be resistant to, or is known to be refractory to, radiation therapy and / or chemotherapy. A cancer is refractory to a therapy when at least a substantial portion of the cancer cells are not killed or their cell division is not stopped in response to the therapy. Such determination can be made in vivo or in vitro by any method known in the art for analyzing the effectiveness of a treatment on cancer cells, using the art-recognized meaning of "refractory" in such contexts. In a specific embodiment, a cancer is refractory where the number of cancer cells has not been significantly reduced or has increased.
[0268] Other cancers that may be treated with the compounds and methods of the present invention include, but are not limited to, cancers and metastases such as brain cancer (glioblastoma) and melanoma, as well as other common tumors.
[0269] In a specific embodiment, leukoplakia (a benign appearing epithelial proliferative or dysplastic lesion) and Bowen's disease (a carcinoma in situ) are pre-neoplastic lesions indicating a need for prophylactic intervention.
[0270] In another embodiment, fibrocystic diseases (cystic hyperplasia, mammary dysplasia, and particularly adenosis (benign epithelial hyperplasia)) indicate a need for prophylactic intervention.
[0271] The preventive use of the compounds and methods of the present invention is also applicable to some viral infections that may cause cancer. For example, human papillomavirus can cause cervical cancer (see, for example, Hernandez-Avila et al., Archives of Medical Research (1997) 28: 265-271), Epstein-Barr virus (EBV) can cause lymphoma (see, for example, Herrmann et al., J. Pathol. (2003) 199 (2): 140-5), hepatitis B or hepatitis C virus can cause liver cancer (see, for example, El-Serag, J. Clin. Gastroenterol. (2002) 35 (5 Suppl 2):S72-8), human T-cell leukemia virus (HTLV)-I can cause T-cell leukemia (see, e.g., Mortreux et al., Leukemia (2003) 17(1):26-38), human herpesvirus-8 infection can cause Kaposi's sarcoma (see, e.g., Kadow et al., Curr. Opin. Investig. Drugs (2002) 3(11):1574-9), and human immunodeficiency virus (HIV) infection promotes cancer development due to immune deficiency (see, e.g., Dal Maso et al., Lancet Oncol. (2003) 4(2):110-9).
[0272] In other embodiments, subjects exhibiting one or more of the following predisposing factors for malignancies can be treated by administering the HDAC6I of the present invention and the methods of the present invention: chromosomal translocations associated with malignancies (e.g., Philadelphia chromosome in chronic myeloid leukemia, t(14;18) in follicular lymphoma, etc.), familial polyposis or Gardner syndrome (a possible precursor to colon cancer), benign monoclonal gammopathy (a possible precursor to multiple myeloma), and subjects with cancer or precancerous diseases that exhibit a Mendelian (genetic) inheritance pattern (e.g., familial colon polyposis, Gardner syndrome, hereditary exostoses, multiple endocrine neoplasia, medullary thyroid carcinoma and pheochromocytoma with amyloid production, Peutz-Jeghers syndrome, neurofibromatosis of Von Recklinghausen, and pheochromocytoma). Recklinghausen), retinoblastoma, carotid body tumors, cutaneous melanoma, intraocular melanoma, xeroderma pigmentosum, ataxia telangiectasia, Chediak-Higashi syndrome, albinism, Fanconi aplastic anemia, and Bloom's syndrome (see Robbins and Angell, 1976, Basic Pathology, 2nd ed., WB Saunders Co., Philadelphia, pp. 112-113 et seq.), and exposure to carcinogens (e.g., smoking and inhalation or contact with certain chemicals).
[0273] In another specific embodiment, the HDAC6I and methods of the invention are administered to a human subject to prevent the progression of breast, colon, ovarian, or cervical cancer.
[0274] In one embodiment, the present invention provides a method for treating cancer, comprising (a) administering a certain amount of HDAC6I of the present invention to an individual in need thereof; and (b) administering one or more additional anti-cancer treatments to the individual, including but not limited to radiotherapy, chemotherapy (including certain antibodies, such as antibodies to PD-1 and PD-L1), surgery, or immunotherapy (e.g., cancer vaccines). In one embodiment, the administration of step (a) is before the administration of step (b). In another embodiment, the administration of step (a) is after the administration of step (b). In another embodiment, the administration of step (a) is in parallel with the administration of step (b).
[0275] In one embodiment, the additional anti-cancer treatment modality is radiation therapy and / or chemotherapy. In another embodiment, the additional anti-cancer treatment modality is surgery.
[0276] In another embodiment, the additional anti-cancer treatment modality is immunotherapy, such as a cancer vaccine.
[0277] In one embodiment, the HDAC6I of the present invention or a pharmaceutically acceptable salt thereof is administered adjunctively with another anti-cancer treatment modality.
[0278] In a preferred embodiment, the additional anti-cancer treatment modality is radiation therapy. In the methods of the present invention, any radiation therapy regimen may be used depending on the type of cancer to be treated. Embodiments of the present invention utilize electromagnetic radiation of various wavelengths: gamma radiation (10 -20 to 10 -13 m), X-ray radiation (10 -12 to 10 -9 m), ultraviolet light (10nm to 400nm), visible light (400nm to 700nm), infrared radiation (700nm to 1mm) and microwave radiation (1mm to 30cm).
[0279] For example, but not limited to, X-ray radiation can be administered; in particular, high-energy megavoltage (radiation with energies greater than 1 MeV) can be used for deep tumors, and electron beam and orthovoltage X-ray radiation can be used for skin cancers. Gamma-emitting radioisotopes, such as radioisotopes of radium, cobalt, and other elements, can also be administered. Illustrative radiation therapy regimens that can be used in the present invention include, but are not limited to, stereotactic methods, in which multiple low-dose radiation sources are simultaneously focused into a tissue volume from multiple angles; "internal radiation therapy," such as brachytherapy, interstitial irradiation, and intracavitary irradiation, which involves placing radioactive implants directly into a tumor or other target tissue; intraoperative irradiation, in which large doses of external radiation are directed at target tissue exposed during surgery; and particle beam radiation therapy, which involves the use of fast-moving subatomic particles to treat localized cancers.
[0280] Many cancer treatment regimens currently utilize radiosensitizers that are activated by electromagnetic radiation (e.g., X-rays). Examples of X-ray activated radiosensitizers include, but are not limited to, metronidazole, misonidazole, desmethyl misonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FUdR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives thereof.
[0281] Photodynamic therapy (PDT) of cancer uses visible light as a radiation activator for sensitizers. Examples of photodynamic radiation sensitizers include but are not limited to: hematoporphyrin derivatives, Benzoporphyrin derivatives, NPe6, tin eptoporphyrin (SnET2), pheoborbide-a, bacteriochlorophyll-a, naphthalocyanine, phthalocyanine, zinc phthalocyanine and therapeutically effective analogs and derivatives thereof.
[0282] In addition to the HDAC6I of the present invention, the radiosensitizer can also be administered in combination with a therapeutically effective amount of one or more compounds, including but not limited to compounds that promote the incorporation of the radiosensitizer into target cells; compounds that control the flow of therapeutic agents, nutrients and / or oxygen to target cells; chemotherapeutic agents that act on tumors with or without additional radiation; or other therapeutically effective compounds for treating cancer or other diseases. Examples of additional therapeutic agents that can be used in combination with radiosensitizers include but are not limited to 5-fluorouracil (5-FU), leucovorin, oxygen, carbogen, red blood cell transfusions, perfluorocarbons (e.g., -DA), 2,3-DPG, BW12C, calcium channel blockers, pentoxifylline, antiangiogenic compounds, hydralazine, and L-BSO.
[0283] In one embodiment, the HDAC6I of the present invention or a pharmaceutically acceptable salt thereof is administered prior to the administration of radiation therapy and / or chemotherapy.
[0284] In another embodiment, the HDAC6I of the present invention or a pharmaceutically acceptable salt thereof is administered adjunctively with radiotherapy and / or chemotherapy.
[0285] The HDAC6I of the present invention and another treatment modality can act additively or synergistically (i.e., the combination of the HDAC6I of the present invention or a pharmaceutically acceptable salt thereof and another anti-cancer treatment modality is more effective than the additive effect of each of them when administered alone). The synergistic combination allows the use of a lower dose of the HDAC6I of the present invention and / or another treatment modality to a subject suffering from cancer, and / or less frequent administration of the HDAC6I of the present invention and / or another treatment modality. The ability to use a lower dose of the HDAC6I of the present invention and / or another treatment modality and / or less frequent administration of the compound of the present invention and another treatment modality can reduce the toxicity associated with administration without reducing the efficacy of the HDAC6I of the present invention and / or another treatment modality in cancer treatment. In addition, the synergistic effect can improve the efficacy of cancer treatment and / or reduce adverse or unnecessary side effects associated with the administration of the HDAC6I of the present invention and / or another anti-cancer treatment modality as a monotherapy.
[0286] In one embodiment, the HDAC6I of the present invention can act synergistically with radiation therapy when administered at a dose typically employed when such HDAC6I is used alone to treat cancer. In another embodiment, the HDAC6I of the present invention can act synergistically with radiation therapy when administered at a dose lower than the dose typically employed when such HDAC6I is used as a monotherapy to treat cancer.
[0287] In one embodiment, radiation therapy can act synergistically with the HDAC6I of the present invention when administered at doses typically employed when using radiation therapy as a monotherapy to treat cancer. In another embodiment, radiation therapy can act synergistically with the compounds of the present invention when administered at doses lower than those typically employed when using radiation therapy as a monotherapy to treat cancer.
[0288] By using techniques known in the art, determining the survival rate after treatment in vitro and / or in vivo, it is possible to determine the effectiveness of HDAC6I as an HDAC6 inhibitor to sensitize cancer cells to the effects of radiotherapy. In one embodiment, for in vitro determination, exponentially growing cells can be exposed to a known dose of radiation, and the survival rate of the cells can be monitored. The irradiated cells are plated and cultured for about 14 to about 21 days, and the colonies are stained. The survival fraction is the number of colonies divided by the efficiency of the plated cells that are not irradiated. The survival fraction on the logarithmic scale is plotted against the absorbed dose on the linear scale to generate a survival curve. The survival curve generally shows that after the initial shoulder region where the dose is sublethal, the proportion of surviving cells decreases exponentially at higher radiation doses. When used in the combination therapy of the present invention, similar schemes can be used for chemical agents.
[0289] In vivo studies can further assess the inherent radiosensitivity of tumor cells and environmental influences, such as hypoxia and host immunity. Growth delay assays are commonly used. This assay measures the time interval required for a tumor exposed to radiation to grow back to a specified volume. 50 The analysis determined the dose required to control approximately 50% of tumors.
[0290] In vivo analysis systems typically utilize transplantable solid tumor systems in experimental subjects. Radiation survival parameters of normal tissues as well as tumors can be analyzed using in vivo methods known in the art.
[0291] The present invention provides a method for treating cancer, comprising administering an effective amount of an HDAC6I of the present invention in combination with established surgical, radiotherapy, and chemotherapy methods, including, for example, chemotherapeutic agents based on radiotherapy mimetics, thereby achieving a synergistic enhancement of the effectiveness of established therapies. The effectiveness of the treatment can be measured in clinical studies or model systems, such as mouse tumor models or cell culture sensitivity assays.
[0292] The present invention provides combination therapies with improved efficacy and / or reduced toxicity.Thus, in one aspect, the present invention relates to the use of the HDAC6I of the present invention as a radiosensitizer in combination with radiotherapy.
[0293] When the combination therapy of the present invention includes administering HDAC6I of the present invention and one or more additional anticancer agents, the HDAC6I of the present invention and the additional anticancer agents can be administered to an individual in parallel or sequentially. The agent can also be administered periodically. Cycling therapy involves administering one or more anticancer agents over a period of time, followed by administering one or more different anticancer agents over a period of time, and repeating this sequential administration (i.e., cycling) to reduce resistance to the one or more anticancer agents administered, avoid or reduce the side effects of the one or more anticancer agents administered, and / or improve therapeutic efficacy.
[0294] The additional anticancer agent can be administered over a series of treatment courses; any one or a combination of the additional anticancer agents listed below can be administered.
[0295] The present invention includes a method for treating cancer, comprising administering an HDAC6I of the present invention and one or more additional anticancer agents or pharmaceutically acceptable salts thereof to a subject in need thereof. The HDAC6I of the present invention and the additional anticancer agents may act additively or synergistically. Suitable anticancer agents include, but are not limited to, gemcitabine, capecitabine, methotrexate, paclitaxel, taxotere, and the like.
[0296] In addition, the present invention provides methods for treating cancer using an HDAC6I of the present invention as an alternative to chemotherapy alone or radiotherapy alone, wherein chemotherapy or radiotherapy has proven or may prove to be too toxic to the subject being treated, for example, resulting in unacceptable or intolerable side effects. The subject being treated may optionally be treated with another anti-cancer treatment modality, such as chemotherapy, surgery, or immunotherapy, depending on which treatment is found to be acceptable or tolerable.
[0297] The HDAC6I of the present invention can also be used in vitro or ex vivo, for example, to treat certain cancers, including but not limited to leukemia and lymphoma, where such treatment involves autologous stem cell transplantation. This can involve a multi-step process in which the subject's autologous hematopoietic stem cells are harvested and cleared of all cancer cells, followed by administration of an effective amount of the HDAC6I of the present invention to the subject to eradicate the subject's remaining bone marrow cell population, followed by the stem cell transplant being returned to the subject. Supportive care is then provided while bone marrow function is restored and the subject recovers.
[0298] The methods of the present invention for treating cancer may also include administering an HDAC6I of the present invention and another therapeutic agent or a pharmaceutically acceptable salt or hydrate thereof. In one embodiment, a composition comprising an HDAC6I of the present invention is administered concurrently with administration of one or more additional therapeutic agents, which may be part of the same composition or in a different composition than the composition comprising the HDAC6I of the present invention. In another embodiment, the HDAC6I of the present invention is administered before or after administration of the additional therapeutic agent.
[0299] In the method of the present invention for treating cancer, the other therapeutic agent may be an antiemetic. Suitable antiemetics include, but are not limited to, metoclopramide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, diethylphylline, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenhydramine, dolasetron, meclizine, methalal, metoprazine, nabilone, oxypentyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, and tropisetron.
[0300] In one embodiment, the antiemetic is granisetron or ondansetron. In another embodiment, the other therapeutic agent can be a hematopoietic colony stimulating factor. Suitable hematopoietic colony stimulating factors include, but are not limited to, filgrastim, sargramostim, mograstim, and epoietin alfa.
[0301] In another embodiment, the other therapeutic agent can be an opioid or a non-opioid analgesic. Suitable opioid analgesics include, but are not limited to, morphine, heroin, hydromorphone, hydrocodone, oxymorphone, oxycodone, methotrexate, apomorphine, normorphine, etorphine, buprenorphine, pethidine, loperamide, anileridine, ethoheptazine, pimidine, betarodine, diphenoxylate, fentanyl, sufentanil, alfentanil, remifentanil, levorphanol, dextromethorphan, phenazocine, pentazocine, cyclazocine, methadone, isomethadone, and propoxyphene. Suitable non-opioid analgesics include, but are not limited to, aspirin, celecoxib, rofecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, indomethacin, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, piroxicam, and sulindac.
[0302] In another embodiment, the other therapeutic agent may be an anxiolytic. Suitable anxiolytics include, but are not limited to, buspirone and benzodiazepines such as diazepam, lorazepam, oxazepam, chlordiazepoxide dipotassium, clonazepam, chlordiazepoxide, and alprazolam.
[0303] In addition to treating cancer and sensitizing cancer cells to the cytotoxic effects of radiotherapy and chemotherapy, the HDAC6I of the present invention is also used in methods for treating central nervous system diseases, disorders and injuries (e.g., neurological diseases, neurodegenerative disorders and traumatic brain injury (TBI)). In a preferred embodiment, the HDAC6I of the present invention is able to cross the blood-brain barrier to inhibit HDAC in the brain of an individual.
[0304] The HDAC6I compound of the present invention also provides therapeutic benefits in peripheral neuropathy (such as CMT) models. Studies have found that HDAC6 inhibitors cross the blood-nerve barrier and rescue the phenotype observed in transgenic mice showing symptoms of distal hereditary motor neuropathy. Administration of HDAC6 inhibitors to symptomatic mice increases acetylated α-tubulin levels, restores proper mitochondrial movement and axonal transport, and increases muscle reinnervation. Other peripheral neuropathies include, but are not limited to, giant axonal neuropathy and various forms of mononeuropathy, polyneuropathy, autonomic neuropathy, and neuritis.
[0305] The HDAC6I compounds of the present invention also improve associative memory loss caused by elevated Aβ or tau protein. In this test, mice were infused with Aβ42 via a cannula implanted in the dorsal hippocampus 15 minutes before training. Two hours before training, the test compound was administered intraperitoneally (25 mg / kg). Fear learning was assessed 24 hours later.
[0306] Contextual fear conditioning performed 24 hours after training showed that freezing was reduced in mice infused with Aβ compared to mice infused with the vehicle. Treatment with the compounds of the invention improved freezing response deficits in mice infused with Aβ, but had no effect on mice infused with the vehicle. The test compound alone did not affect the memory performance of the mice. In addition, treatment had no effect on motor, sensory or motivational skills, as assessed using a visible platform test in which the compound was injected twice a day for two days. During these experiments, no obvious signs of toxicity were observed, including changes in food and fluid intake, weight loss, or changes in movement and exploratory behavior.
[0307] These results demonstrate that the HDAC6I of the present invention is beneficial for counteracting the impairment of associative memory following the elevation of certain proteins including Aβ and tau.
[0308] Therefore, the HDAC6I of the present invention can be used to treat nervous system diseases by administering an amount of the HDAC6I of the present invention that is effective for treating nervous system diseases, or by administering a pharmaceutical composition comprising an amount of the HDAC6I of the present invention that is effective for treating nervous system diseases. Neurological diseases that may be treated include, but are not limited to, Huntington's disease, lupus, schizophrenia, multiple sclerosis, muscular dystrophy, dentatorubral pallidum Lewy body atrophy (DRRLA), spinal bulbar muscular atrophy (SBMA) and fine spinocerebellar ataxias (SCA1, SCA2, SCA3 / MJD (Machado-Joseph disease), SCA6, and SCA7), drug-induced movement disorders, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, Pick's disease, Alzheimer's disease, dementia with Lewy bodies, corticobasal degeneration, dystonia, myoclonus, Tourette syndrome, tremor, chorea, restless legs syndrome, Parkinson's disease, parkinsonian syndromes, anxiety, depression, psychosis, manic-depressive disorder, Friedreich's ataxia, fragile X syndrome, spinal muscular dystrophy, Rett syndrome, Rubinstein-Taybi syndrome, Wilson's disease, multi-infarct states, CMT, GAN, and other peripheral neuropathies.
[0309] In one embodiment, the neurological disease treated is Huntington's disease, Parkinson's disease, Alzheimer's disease, Down syndrome, spinal muscular atrophy, lupus, or schizophrenia.
[0310] Charcot-Marie-Tooth disease (CMT) is the most common inherited neurological disorder, affecting approximately 1 in 2,500 people in the United States. CMT affects both motor and sensory nerves, which can lead to foot drop and a high-stepping gait with frequent stumbling or falling. Mutations in the small heat shock protein 27 (HSPB1) gene cause axonal CMT, or distal hereditary motor neuropathy (distal HMN). Expression of mutant HSPB1 reduces levels of acetylated α-tubulin and induces severe axonal transport defects. Pharmacological inhibition of histone deacetylase 6 (HDAC6)-induced α-tubulin deacetylation by the HDAC6I tubastatin A corrects the axonal transport defects induced by HSPB1 mutations and rescues the CMT phenotype in symptomatic mutant HSPB1 mice. The pathogenic role of α-tubulin deacetylation has been demonstrated in mutant HSPB1-induced neuropathy and offers valuable prospects for HDAC6 inhibitors as therapeutic strategies for inherited axonal diseases. The compounds of the present invention exhibit potent HDAC6 isoform inhibition, high HDAC6 selectivity, and impressive α-tubulin acetylation in various cell lines.
[0311] Thus, in another embodiment, the neurological disease is Charcot-Marie-Tooth disease. Current studies using CMT2A mutant animals have shown that some of the HDAC6Is of the present invention are able to correct the motor and sensory problems of these animals and restore their performance to levels similar to those shown by wild-type animals.
[0312] HDAC6I of the present invention can also be used in combination with a second therapeutic agent in methods for treating CNS disorders, diseases, and injuries. Such second therapeutic agents are those known in the art for treating specific disorders, diseases, or injuries, such as, but not limited to, lithium for treating mood disorders, estradiol benzoate, and nicotinamide for treating Huntington's disease.
[0313] The HDAC6I of the present invention can also be used to treat TBI. Traumatic brain injury (TBI) is a severe and complex injury that affects approximately 1.4 million people in the United States each year. TBI is associated with a variety of symptoms and disabilities, including risk factors for developing neurodegenerative disorders such as Alzheimer's disease.
[0314] TBI produces multiple pathologies, including axonal injury, cell death, contusion, and inflammation. The inflammatory cascade is characterized by activation of proinflammatory cytokines and microglia, which exacerbate these other pathologies. Despite the well-established role of inflammation in TBI, no effective anti-inflammatory therapy is currently available for the treatment of TBI.
[0315] Several known HDAC inhibitors have been found to have protective effects in various cellular and animal models of acute and chronic neurodegenerative injury and disease, such as Alzheimer's disease, ischemic stroke, multiple sclerosis (MS), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and spinal bulbar muscular atrophy (SBMA). A recent study of experimental pediatric TBI reported a decrease in hippocampal CA3 histone H3 acetylation that persisted for hours to days after injury. These changes have been attributed to the documented upstream excitotoxic and stress cascades associated with TBI. HDAC6I has also been reported to exert anti-inflammatory effects through the acetylation of non-histone proteins. The study found that the HDAC6 selective inhibitor 4-dimethylamino-N-[5-(2-mercaptoacetamido)pentyl]benzamide (DMA-PB) increased histone H3 acetylation and reduced microglial inflammatory responses in rats after traumatic brain injury, demonstrating the utility of HDAC6I as a therapeutic agent for inhibiting neuroinflammation associated with TBI.
[0316] Therefore, the HDAC6I of the present invention can also be used to treat inflammation and stroke, as well as to treat autism and autism spectrum disorders. The HDAC6I of the present invention can also be used to treat parasitic infections (such as malaria, toxoplasmosis, trypanosomiasis, helminthiasis and protozoan infections (see Andrews et al. Int. J. Parasitol. 2000, 30 (6), 761-768).
[0317] The present invention HDAC6I can also be used as an imaging agent. Specifically, by providing radiolabeled, isotope-labeled or fluorescently labeled HDAC6I, the labeled compound can image HDAC, HDAC-expressing tissues and tumors. By administering an effective amount of a labeled compound or a composition containing a labeled compound, the labeled HDAC6I of the present invention can also be used to image patients with cancer or other HDAC-mediated diseases (such as stroke). In a preferred embodiment, the labeled HDAC6I can emit positron radiation and is suitable for positron emission tomography (PET). Typically, the labeled HDAC6I of the present invention is used to identify areas expressing high concentrations of HDAC in tissues or targets. Known methods for quantifying radioactive emissions can be used to quantify the accumulation of labeled HDAC6I. In addition, the labeled HDAC6I can contain a fluorophore or similar reporter gene that can track the movement of specific HDAC isoforms or organelles in vitro.
[0318] The HDAC6I of the present invention that can be used in imaging methods contains one or more radioactive isotopes that are capable of emitting one or more forms of radiation suitable for detection by any standard radiological equipment (e.g., PET, SPECT, gamma cameras, MRI, and the like). Preferred isotopes include tritium ( 3 H) and carbon ( 11 C). The substituted HDAC6I of the present invention may also contain fluorine ( 18 F) and iodine ( 123 I) isotopes for use in imaging methods. Typically, the labeled HDAC6I of the present invention contains 11 C-labeled alkyl or aryl (i.e., 11 C-methyl), or 18 F. 123 I. 125 I. 131 I or a combination thereof substituted alkyl or aryl.
[0319] Fluorescently labeled HDAC6I of the present invention can also be used in the imaging methods of the present invention. Such compounds have FITC, carbocyanine moieties or other fluorophores, which will allow the visualization of HDAC proteins in vitro.
[0320] Labeled HDAC6I and methods of use can be performed in vivo, particularly in humans, and can be used for in vitro applications, such as diagnostic and research applications using body fluids and cell samples. Imaging methods using the labeled HDAC6I of the present invention are discussed in WO03 / 060523, which specifies the United States and is incorporated herein in its entirety. Typically, the method comprises contacting a cell or tissue with a radiolabeled, isotopically labeled, fluorescently labeled, or labeled (e.g., biotin-labeled) compound of the present invention, and making a radioactive, fluorescent, or similar type of image according to the visualization method employed, i.e., in terms of a radiographic image, an amount sufficient to provide about 1 to about 30 mCi of a radiolabeled compound.
[0321] Preferred imaging methods include the use of labeled HDAC6I of the invention that are capable of generating a target:background radiation intensity ratio of at least 2:1, or more preferably a target to background radiation intensity ratio of about 5:1, about 10:1, or about 15:1.
[0322] In a preferred method, the labeled HDAC6I of the present invention is rapidly excreted from body tissues, thereby preventing long-term exposure to radiation from the radiolabeled compound administered to the individual. Typically, the labeled HDAC6I of the present invention is eliminated from the body in less than about 24 hours. More preferably, the labeled HDAC6I is eliminated from the body in less than about 16 hours, 12 hours, 8 hours, 6 hours, 4 hours, 2 hours, 90 minutes or 60 minutes. Typically, the preferred labeled HDAC6I is eliminated in about 60 to about 120 minutes.
[0323] In addition to isotopically labeled and fluorescently labeled derivatives, the present invention also embodies the use of derivatives containing tags (eg, biotin) to identify biomolecules related to the HDAC isoform of interest for diagnostic, therapeutic, or research purposes.
[0324] The HDAC6I of the present invention can also be used to treat autoimmune diseases and inflammation. The compounds of the present invention are particularly useful for overcoming transplant and transplant rejection and treating various forms of arthritis.
[0325] Despite the success of modern transplant programs, the nephrotoxicity, cardiovascular disease, diabetes, and hyperlipidemia associated with current treatment regimens, coupled with the incidence of post-transplant malignancies and graft loss due to chronic rejection, have prompted efforts to achieve long-term allograft function and minimal immunosuppression. Similarly, the incidence of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is also increasing. Animal studies have shown that T regulatory cells (Tregs) expressing Foxp3, a member of the forkhead transcription family, are key to limiting autoreactivity and alloreactive immunity. In addition, after inducing Tregs by costimulation blockade, immunosuppression, or other strategies, Tregs can be adoptively transferred to naive hosts to achieve beneficial therapeutic effects. However, attempts to develop enough Tregs to maintain suppressive function after transfer in clinical trials have failed. Murine studies have shown that HDAC6I limits immune responses, at least to a large extent, by increasing Treg suppressive function (R. Tao et al., Nat. Med, 13, 1299-1307 (2007)), and selective targeting of HDAC6 is particularly effective in this regard.
[0326] For organ transplantation, rejection begins to develop within the first few days after transplantation, so preventing rejection rather than treating it is a primary consideration. The opposite is true for autoimmunity, where the patient's disease has already caused problems. Therefore, it was evaluated whether HDAC6- / - mice treated with low-dose RPM (rapamycin) for 14 days showed signs of tolerance induction and resistance to the development of chronic rejection, a long-term, severe loss of graft function in the clinical transplant population. Tolerance was assessed by testing whether mice with long-term surviving allografts rejected subsequent third-party heart transplants and received additional donor allografts in the absence of any immunosuppression, as would occur using non-selective HDAC6I plus RPM. These in vivo studies were accompanied by assessment of ELISPOT and MLR activity using recipient lymphocytes challenged with donor cells. Protection against chronic rejection was assessed by analyzing host anti-donor humoral responses and analyzing graft arteriosclerosis and interstitial fibrosis in long-term surviving allograft recipients.
[0327] The importance of targeting HDAC6 was assessed in additional transplantation models, seeking biochemically meaningful readouts similar to those monitored clinically. Therefore, targeting HDAC6 was evaluated in kidney transplant recipients (monitoring blood urea nitrogen (BUN) and proteinuria) and pancreatic islet allografts (monitoring blood glucose levels). Kidney transplantation is the most commonly performed organ transplant, and the kidney performs multiple functions, such as regulating acid / base metabolism, blood pressure, and erythropoiesis, so efficacy in this model demonstrates the utility of HDAC6 targeting. Similarly, given that clinical islet allografts are typically lost within the first year or two after transplantation, islet transplantation represents a significant unmet need. A safe and nontoxic method to prolong islet survival without the need for maintenance CNI therapy would be a significant advance. Transplantation studies have also been enhanced by using mice harboring floxed HDAC6. For example, using the existing Foxp3-Cre mouse, the effects of HDAC6 deletion exclusively in Tregs were tested. For example, this approach could be extended to targeting HDAC6 in both T cells (CD4-Cre) and dendritic cells (CD11c-Cre). The importance of HDAC6 in transplantation induction versus maintenance was assessed by administering tamoxifen at various times post-transplantation and inducing HDAC6 deletion using tamoxifen-regulated Cre (with implications for short-term versus maintenance HDAC6I therapy).
[0328] Autoimmune studies have also been conducted. In this case, it is particularly important to interrupt the existing disease, and HDAC6 targeting is effective without any additional therapy (in contrast to the need for short-term low-dose RPM in very aggressive, completely MHC-mismatched transplant models). Studies on mice with colitis have shown that HDAC6- / -Treg is more effective than WT Treg in regulating the disease, and if treatment is started after colitis has developed, tubacin can save mice. These studies have been expanded by assessing whether HDAC6 deletion in Treg (Foxp3 / Cre) relative to T cells (CD4=Cre) relative to DC (CD11c-Cre) has different effects on the development and severity of colitis. Similarly, control of colitis was assessed by inducing HDAC6 deletion at different time intervals with tamoxifen-regulated Cre after the onset of colitis.
[0329] It is expected that the compounds of the present invention will show anti-arthritis efficacy in the collagen-induced arthritis model of DBA1 / J mice. In this test, DBA1 / J mice (male, 7-8 weeks) were used, with 8 animals per group. Systemic arthritis was induced with bovine collagen type II and CFA, and an IFA booster injection was injected on the 21st day. On the 28th day, HDAC6I of the present invention was administered at 50 mg / kg and 100 mg / kg for 2 consecutive weeks, and the effect was determined by the average arthritis score relative to the treatment day data.
[0330] Despite efforts to avoid graft rejection through host-donor tissue type matching, immunosuppressive therapy is crucial for the viability of the donor organ within the host in most transplant procedures. A variety of immunosuppressive agents are used in transplant procedures, including azathioprine, methotrexate, cyclophosphamide, FK-506, rapamycin, and corticosteroids.
[0331] The HDAC6I of the present invention is a potent immunosuppressant that inhibits humoral and cell-mediated immune responses, such as allograft rejection, delayed-type hypersensitivity reactions, experimental allergic encephalomyelitis, Freund's adjuvant arthritis, and graft-versus-host disease. The HDAC6I of the present invention can be used to prevent organ rejection after organ transplantation, treat rheumatoid arthritis, treat psoriasis, and treat other autoimmune diseases, such as type 1 diabetes, Crohn's disease, and lupus.
[0332] Therapeutically effective amounts of HDAC6I of the present invention can be used for immunosuppression, including, for example, preventing organ rejection or graft-versus-host disease, and treating diseases and disorders, particularly autoimmune and inflammatory diseases and disorders. Examples of autoimmune and inflammatory diseases include, but are not limited to, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, psoriasis, diabetes, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjögren's syndrome, multiple sclerosis, myasthenia gravis, Reiter's syndrome, arthritis (rheumatoid arthritis, chronic progressive arthritis, and deforming arthritis) and rheumatic diseases, autoimmune blood disorders (hemolytic anemia, aplastic anemia, pure red blood cell anemia, and idiopathic thrombocytopenia), polyps, leukemia, myasthenia gravis, leukemia, rheumatoid arthritis, and rheumatism. osteitis, scleroderma, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (ulcerative colitis and Crohn's disease), endocrine eye diseases, Graves' disease, sarcoidosis, primary biliary cirrhosis, juvenile diabetes mellitus (type 1 diabetes), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, and glomerulonephritis.
[0333] The HDAC6I of the present invention can be used alone or in combination with a second therapeutic agent known to be useful in treating autoimmune diseases, inflammation, transplantation and grafts, such as cyclosporine, rapamycin, methotrexate, cyclophosphamide, azathioprine, corticosteroids and similar agents known to those skilled in the art.
[0334] Additional diseases and conditions mediated by HDAC, particularly HDAC6, include, but are not limited to, asthma, cardiac hypertrophy, giant axonal neuropathy, mononeuropathy, mononeuritis, polyneuropathy, autonomic neuropathy, general neuritis, and general neuropathy. These diseases and conditions can also be treated by the methods of the present invention.
[0335] In the methods of the present invention, a therapeutically effective amount of one or more HDAC6Is of the present invention (generally formulated in accordance with pharmaceutical practice) is administered to a person in need thereof. Whether such treatment is indicated depends on the individual's circumstances and is subject to medical evaluation (diagnosis), which takes into account the presence of signs, symptoms, and / or dysfunction, the risk of developing specific signs, symptoms, and / or dysfunction, and other factors.
[0336] The HDAC6I of the present invention can be administered by any suitable route, for example, orally, buccal, inhaled, topically, sublingually, rectally, vaginally, intracisternal or intrathecal by lumbar puncture, transurethrally, nasally, transdermally (i.e., transdermally) or parenterally (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and / or surgical implantation at a specific site). Parenteral administration can be accomplished using a needle and syringe or using high-pressure technology.
[0337] Pharmaceutical compositions include those in which an HDAC6I of the present invention is present in an amount sufficient to be administered in an effective amount to achieve its intended purpose. The exact formulation, route of administration, and dosage are determined by the individual physician based on the diagnosed condition or disease. The dosage and time interval can be individually adjusted to provide a level of the HDAC6I of the present invention sufficient to maintain a therapeutic effect.
[0338] The toxicity and therapeutic efficacy of the HDAC6I compounds of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as for determining LD 50 (a dose lethal to 50% of the population) and ED 50 (The dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as LD 50 With ED 50The ratio between the two groups is preferred. Compounds that exhibit high therapeutic indices are preferred. Data obtained from such procedures can be used to formulate a dosage range for use in humans. The dosage is preferably within a range of circulating compound concentrations that include the ED with little or no toxicity. 50 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the specific embodiments provided herein.
[0339] The therapeutically effective amount of the HDAC6I of the present invention required for use in therapy varies with the nature of the disease being treated, the length of time required for activity, and the age and condition of the patient, and is ultimately determined by the attending physician. The dosage and time interval can be adjusted individually to provide an HDAC6I plasma level sufficient to maintain the desired therapeutic effect. The desired dose can be conveniently administered as a single dose, or as multiple doses administered at appropriate time intervals, such as once, twice, three times, four times or more sub-doses per day. Multiple doses are usually required or required. For example, the HDAC6I of the present invention can be administered at the following frequency: one dose per day at four-day intervals, delivering four doses (q4d x 4); one dose per day at three-day intervals, delivering four doses (q3d x4); one dose per day at five-day intervals (qd x 5); one dose per week for three weeks (qwk3); five daily doses, two days of rest, and another five daily doses (5 / 2 / 5); or, any dosage regimen appropriate for the situation.
[0340] The dosage of a composition containing HDAC6I of the present invention, or a composition containing the same, can be from about 1 ng / kg to about 200 mg / kg, from about 1 μg / kg to about 100 mg / kg, or from about 1 mg / kg to about 50 mg / kg of body weight. The above dosages are examples of average cases, but there may be individual cases where higher or lower doses are beneficial, and such cases are within the scope of the present invention. In practice, a physician will determine the actual dosing regimen that is most suitable for an individual patient, which may vary depending on the age, weight, and response of the specific patient.
[0341] The HDAC6I of the present invention used in the methods of the present invention is typically administered in an amount of about 0.005 to about 500 mg per dose, about 0.05 to about 250 mg per dose, or about 0.5 to about 100 mg per dose. For example, the HDAC6I of the present invention can be administered in an amount of about 0.005, 0.05, 0.5, 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg per dose, including all doses between 0.005 and 500 mg.
[0342] The HDAC6I of the present invention is typically administered in admixture with a pharmaceutical carrier selected according to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions used according to the present invention are formulated in a conventional manner using one or more physiologically acceptable carriers containing excipients and adjuvants that facilitate the processing of the HDAC6I of the present invention.
[0343] The term "carrier" refers to a diluent, adjuvant, or excipient administered with the HDAC6I of the present invention. Such pharmaceutical carriers can be liquids, such as water and oils, including oils of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Carriers can include physiological saline, gum arabic, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, adjuvants, stabilizers, thickeners, lubricants, and colorants may be used. Pharmaceutically acceptable carriers are sterile. When the HDAC6I of the present invention is administered intravenously, water is a preferred carrier. Physiological saline solutions, aqueous dextrose solutions, and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene glycol, water, and ethanol. If desired, the present compositions may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0344] For example, these pharmaceutical compositions can be manufactured by conventional mixing, dissolving, granulating, dragee-making, emulsifying, encapsulating, embedding, or lyophilizing processes. The appropriate formulation depends on the chosen route of administration. When a therapeutically effective amount of the HDAC6I of the present invention is administered orally, the composition is typically in the form of a tablet, capsule, powder, solution, or elixir. When administered in tablet form, the composition may additionally contain a solid carrier, such as gelatin or an adjuvant. Tablets, capsules, and powders contain from about 0.01% to about 95%, and preferably from about 1% to about 50%, of the HDAC6I of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, or an oil of animal or plant origin may be added. The liquid form of the composition may also contain physiological saline solution, dextrose or other sugar solutions, or glycols. When administered in liquid form, the composition contains from about 0.1% to about 90% by weight, and preferably from about 1% to about 50% by weight, of the compound of the present invention.
[0345] When a therapeutically effective amount of the HDAC6I of the present invention is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions is within the skill of the art, with due regard for pH, isotonicity, stability, and the like. Preferred compositions for intravenous, cutaneous, or subcutaneous injection typically contain an isotonic vehicle. The HDAC6I of the present invention can be infused over a 10-30 minute timeframe or over several hours with other fluids.
[0346] The HDAC6I of the present invention can be easily combined with pharmaceutically acceptable carriers well known in the art. Such carriers enable the active agent to be formulated into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc. for oral ingestion by the patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding the HDAC6I of the present invention to a solid excipient, optionally grinding the resulting mixture, and processing the granular mixture to obtain tablets or dragee cores after adding suitable adjuvants if necessary. Suitable excipients include, for example, fillers and cellulose preparations. If necessary, a disintegrant can be added.
[0347] The HDAC6I of the present invention can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. The formulation for injection can be presented in unit dosage form, for example, in ampoules or in multidose containers, along with an added preservative. The composition can be in the form of a suspension, solution, or emulsion in an oily or aqueous medium and can contain preparatants, such as suspending agents, stabilizers, and / or dispersants.
[0348] Pharmaceutical compositions for parenteral administration include aqueous solutions of active agents in water-soluble form. In addition, the suspension of HDAC6I of the present invention can be prepared as an appropriate oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension. Optionally, the suspension may also contain a suitable stabilizer, or an agent that increases the solubility of the compound and allows the preparation of a highly concentrated solution. Alternatively, the present composition may be in powder form to be reconstituted with a suitable vehicle (e.g., sterile pyrogen-free water) before use.
[0349] The present invention HDAC6I can also be formulated into rectal compositions, such as suppositories or retention enemas, for example, containing conventional suppository bases. In addition to the preparations described previously, the present invention HDAC6I can also be formulated into reservoir preparations. Such long-acting preparations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Therefore, for example, the present invention HDAC6I can be formulated with a suitable polymeric material or hydrophobic material (e.g., formulated as an emulsion in an acceptable oil) or an ion exchange resin.
[0350] Specifically, the HDAC6I of the present invention can be administered orally, buccally, or sublingually in the form of tablets containing excipients (e.g., starch or lactose), or in the form of capsules or ovules (alone or mixed with excipients), or in the form of elixirs or suspensions containing flavorings or colorants. Such liquid preparations can be prepared with pharmaceutically acceptable additives (e.g., suspending agents). The HDAC6I of the present invention can also be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the HDAC6I of the present invention is preferably used in the form of a sterile aqueous solution, which may contain other substances, such as salts or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.
[0351] As another embodiment, the present invention includes a medicine box, which includes one or more compounds or compositions, and the packaging of the compounds or compositions promotes them to be used in practicing the inventive method. In a simple embodiment, the medicine box includes a compound or composition (for example, a composition comprising HDAC6I of the present invention and an optional second therapeutic agent) that can be used for implementing the method as described herein, and the compound or composition is packaged in a container (such as a sealed bottle or container), wherein a label is attached to the container or included in the medicine box, describing the use of the compound or composition to implement the inventive method. Preferably, the compound or composition is packaged in a unit dosage form. The medicine box may also include a device suitable for administering the composition according to the intended route of administration, such as a syringe, an infusion bag or a patch. In another embodiment, the compound of the present invention is a lyophilized product. In this case, the medicine box may also include another container containing a solution that can be used to reconstitute the lyophilized product.
[0352] Existing HDAC6I have properties that hinder their development as therapeutic agents. According to an important feature of the present invention, the HDAC6I of the present invention was synthesized and evaluated as an HDAC inhibitor. The compounds of the present invention show increased HDAC6 efficacy and selectivity for HDAC1 and HDAC8. The improved properties of the compounds of the present invention show that the compounds of the present invention can be used for applications such as, but not limited to, immunosuppressants and neuroprotectants. For example, the inhibitory efficacy (IC) of the compounds of the present invention on HDAC6 50 ) are typically less than 100 μM, less than 25 μM, less than 10 μM, less than 1 μM, less than 0.5 μM, and less than 0.2 μM.
[0353] Uses of HDAC6 inhibitors.
[0354] The HDAC6I of the present invention can be used alone or in combination with a second therapeutic agent known to be useful in treating a variety of diseases including autoimmune diseases, inflammation, or transplantation and graft rejection, such as cyclosporine, rapamycin, methotrexate, cyclophosphamide, azathioprine, corticosteroids, and similar agents known to those skilled in the art.
[0355] Additional diseases and conditions mediated by HDAC, particularly HDAC6, include, but are not limited to, asthma, cardiac hypertrophy, giant axonal neuropathy, mononeuropathy, mononeuritis, polyneuropathy, autonomic neuropathy, general neuritis, and general neuropathy. These diseases and conditions can also be treated by the methods of the present invention.
[0356] In the methods of the present invention, a therapeutically effective amount of one or more HDAC6Is of the present invention (generally formulated in accordance with pharmaceutical practice) is administered to a person in need thereof. Whether such treatment is indicated depends on the individual's circumstances and is subject to medical evaluation (diagnosis), which takes into account the presence of signs, symptoms, and / or dysfunction, the risk of developing specific signs, symptoms, and / or dysfunction, and other factors.
[0357] The HDAC6I of the present invention can be administered by any suitable route, for example, orally, buccal, inhaled, topically, sublingually, rectally, vaginally, intracisternal or intrathecal by lumbar puncture, transurethrally, nasally, transdermally (i.e., transdermally) or parenterally (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and / or surgical implantation at a specific site). Parenteral administration can be accomplished using a needle and syringe or using high-pressure technology.
[0358] Pharmaceutical compositions include those in which an HDAC6I of the present invention is present in an amount sufficient to be administered in an effective amount to achieve its intended purpose. The exact formulation, route of administration, and dosage are determined by the individual physician based on the diagnosed condition or disease. The dosage and time interval can be individually adjusted to provide a level of the HDAC6I of the present invention sufficient to maintain a therapeutic effect.
[0359] The toxicity and therapeutic efficacy of the HDAC6I compounds of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as for determining LD 50 (a dose lethal to 50% of the population) and ED 50 (The dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as LD 50 With ED 50The ratio between the two groups is preferred. Compounds that exhibit high therapeutic indices are preferred. Data obtained from such procedures can be used to formulate a dosage range for use in humans. The dosage is preferably within a range of circulating compound concentrations that include the ED with little or no toxicity. 50 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the specific embodiments provided herein.
[0360] The therapeutically effective amount of the HDAC6I of the present invention required for use in therapy varies with the nature of the disease being treated, the length of time required for activity, and the age and condition of the patient, and is ultimately determined by the attending physician. The dosage and time interval can be adjusted individually to provide an HDAC6I plasma level sufficient to maintain the desired therapeutic effect. The desired dose can be conveniently administered as a single dose, or as multiple doses administered at appropriate time intervals, such as once, twice, three times, four times or more sub-doses per day. Multiple doses are usually required or required. For example, the HDAC6I of the present invention can be administered at the following frequency: one dose per day at four-day intervals, delivering four doses (q4d x 4); one dose per day at three-day intervals, delivering four doses (q3d x4); one dose per day at five-day intervals (qd x 5); one dose per week for three weeks (qwk3); five daily doses, two days of rest, and another five daily doses (5 / 2 / 5); or, any dosage regimen appropriate for the situation.
[0361] The dosage of a composition containing HDAC6I of the present invention, or a composition containing the composition, can be from about 1 ng / kg to about 200 mg / kg, from about 1 μg / kg to about 100 mg / kg, or from about 1 mg / kg to about 50 mg / kg of body weight. The dosage of the composition can be any dosage, including but not limited to about 1 μg / kg, 10 μg / kg to 200 mg / kg. The above dosages are examples of average cases, but there may be individual cases where higher or lower doses are beneficial, and such cases are within the scope of the present invention. In practice, a physician will determine the actual dosing regimen that is most suitable for an individual patient, which may vary depending on the age, weight, and response of the particular patient.
[0362] The HDAC6I of the present invention used in the methods of the present invention is typically administered in an amount of about 0.005 to about 500 mg per dose, about 0.05 to about 250 mg per dose, or about 0.5 to about 100 mg per dose. For example, the HDAC6I of the present invention can be administered in an amount of about 0.005, 0.05, 0.5, 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg per dose, including all doses between 0.005 and 500 mg.
[0363] The HDAC6I of the present invention is typically administered in admixture with a pharmaceutical carrier selected according to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions used according to the present invention are formulated in a conventional manner using one or more physiologically acceptable carriers containing excipients and adjuvants that facilitate the processing of the HDAC6I of the present invention.
[0364] The term "carrier" refers to a diluent, adjuvant, or excipient administered with the HDAC6I of the present invention. Such pharmaceutical carriers can be liquids, such as water and oils, including oils of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Carriers can include physiological saline, gum arabic, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, adjuvants, stabilizers, thickeners, lubricants, and colorants may be used. Pharmaceutically acceptable carriers are sterile. When the HDAC6I of the present invention is administered intravenously, water is a preferred carrier. Physiological saline solutions, aqueous dextrose solutions, and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene glycol, water, and ethanol. If desired, the present compositions may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0365] For example, these pharmaceutical compositions can be manufactured by conventional mixing, dissolving, granulating, dragee-making, emulsifying, encapsulating, embedding, or lyophilizing processes. The appropriate formulation depends on the chosen route of administration. When a therapeutically effective amount of the HDAC6I of the present invention is administered orally, the composition is typically in the form of a tablet, capsule, powder, solution, or elixir. When administered in tablet form, the composition may additionally contain a solid carrier, such as gelatin or an adjuvant. Tablets, capsules, and powders contain from about 0.01% to about 95%, and preferably from about 1% to about 50%, of the HDAC6I of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, or an oil of animal or plant origin may be added. The liquid form of the composition may also contain physiological saline solution, dextrose or other sugar solutions, or glycols. When administered in liquid form, the composition contains from about 0.1% to about 90% by weight, and preferably from about 1% to about 50% by weight, of the compound of the present invention.
[0366] When a therapeutically effective amount of the HDAC6I of the present invention is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions is within the skill of the art, with due regard for pH, isotonicity, stability, and the like. Preferred compositions for intravenous, cutaneous, or subcutaneous injection typically contain an isotonic vehicle. The HDAC6I of the present invention can be infused over a 10-30 minute timeframe or over several hours with other fluids.
[0367] The HDAC6I of the present invention can be easily combined with pharmaceutically acceptable carriers well known in the art. Such carriers enable the active agent to be formulated into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc. for oral ingestion by the patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding the HDAC6I of the present invention to a solid excipient, optionally grinding the resulting mixture, and processing the granular mixture to obtain tablets or dragee cores after adding suitable adjuvants if necessary. Suitable excipients include, for example, fillers and cellulose preparations. If necessary, a disintegrant can be added.
[0368] The HDAC6I of the present invention can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. The formulation for injection can be presented in unit dosage form, for example, in ampoules or in multidose containers, along with an added preservative. The composition can be in the form of a suspension, solution, or emulsion in an oily or aqueous medium and can contain preparatants, such as suspending agents, stabilizers, and / or dispersants.
[0369] Pharmaceutical compositions for parenteral administration include aqueous solutions of active agents in water-soluble form. In addition, suspensions of HDAC6I of the present invention can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension.
[0370] Optionally, the suspension may also contain suitable stabilizers, or agents which increase the solubility of the compound and allow the preparation of highly concentrated solutions. Alternatively, the compositions of the invention may be in powder form for reconstitution with a suitable vehicle (eg, sterile pyrogen-free water) before use.
[0371] The present invention HDAC6I can also be formulated into rectal compositions, such as suppositories or retention enemas, for example, containing conventional suppository bases. In addition to the preparations described previously, the present invention HDAC6I can also be formulated into reservoir preparations. Such long-acting preparations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Therefore, for example, the present invention HDAC6I can be formulated with a suitable polymeric material or hydrophobic material (e.g., formulated as an emulsion in an acceptable oil) or an ion exchange resin.
[0372] Specifically, the HDAC6I of the present invention can be administered orally, buccally, or sublingually in the form of tablets containing excipients (e.g., starch or lactose), or in the form of capsules or ovules (alone or mixed with excipients), or in the form of elixirs or suspensions containing flavorings or colorants. Such liquid preparations can be prepared with pharmaceutically acceptable additives (e.g., suspending agents). The HDAC6I of the present invention can also be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the HDAC6I of the present invention is preferably used in the form of a sterile aqueous solution, which may contain other substances, such as salts or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.
[0373] As another embodiment, the present invention includes a medicine box, which includes one or more compounds or compositions, and the packaging of the compounds or compositions promotes them to be used in practicing the inventive method. In a simple embodiment, the medicine box includes a compound or composition (for example, a composition comprising HDAC6I of the present invention and an optional second therapeutic agent) that can be used for implementing the method as described herein, and the compound or composition is packaged in a container (such as a sealed bottle or container), wherein a label is attached to the container or included in the medicine box, describing the use of the compound or composition to implement the inventive method. Preferably, the compound or composition is packaged in a unit dosage form. The medicine box may also include a device suitable for administering the composition according to the intended route of administration, such as a syringe, an infusion bag or a patch. In another embodiment, the selected compound is a lyophilized product. In this case, the medicine box may also include another container containing a solution that can be used to reconstitute the lyophilized product.
[0374] Many existing HDAC6Is have properties that may hinder their development as therapeutic agents for diseases other than cancer because they generally show activity against many known HDACs. Therefore, an important feature of the present invention relates to the fact that the compounds of the present invention show isotype selectivity. Relative to other HDACs, the compounds of the present invention show increased inhibitory efficacy and selectivity for HDAC6, particularly higher selectivity for Class II than Class I. The improved properties of the compounds of the present invention indicate that these compounds should be useful for applications such as, but not limited to, immunosuppressants and neuroprotectants, as well as Alzheimer's disease, depression, Rett syndrome, Charcot-Marie-Tooth disease, brain cancer and other diseases. For example, the binding affinity (IC) of the compounds of the present invention to HDAC6 is 50 ) are typically less than 1 μM, and in some cases less than 10 nM.
[0375] definition
[0376] As used herein, the following terms and expressions have the indicated meanings.
[0377] As used herein, terms may be preceded and / or followed by a single dash "-" or a double dash "=" to indicate the order of the bond between the designated substituent and its parent moiety; a single dash indicates a single bond and a double dash indicates a double bond. In the absence of a single or double dash, a single bond is understood to be formed between the substituent and its parent moiety; furthermore, substituents are intended to be read "left to right" unless otherwise indicated by a dash. For example, C1-C6 alkoxycarbonyloxy and -OC(O)OC1-C6 alkyl indicate the same functional group; similarly, arylalkyl and -alkylaryl indicate the same functional group.
[0378] "Acetyl" means a group of formula -C(O)CH3.
[0379] "Alkenyl" means a straight or branched chain hydrocarbon containing 2 to 10 carbon atoms (unless otherwise specified) and containing at least one carbon-carbon double bond. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl, and 3,7-dimethylocta-2,6-dienyl.
[0380] "Alkynyl" means a straight or branched chain hydrocarbon radical containing 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 3-butynyl, and 2-pentynyl.
[0381] "Alkoxy" means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
[0382] "Alkyl" means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms (unless otherwise specified). Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. When "alkyl" is a linking group between two other moieties, it can also be straight or branched; examples include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2C(CH3)2-, and -CH2CH(CH2CH3)CH2-.
[0383] "Aryl" means phenyl (i.e., a monocyclic aryl), or a bicyclic ring system containing at least one phenyl ring, or an aromatic bicyclic ring containing only carbon atoms in the aromatic bicyclic ring system. Bicyclic aryl groups can be azulenyl, naphthyl, etc. The aryl group is attached to the parent molecular moiety through any carbon atom contained in the aromatic ring system. One or two hydrogen atoms that are part of the aryl group can be replaced by a substituent selected from the group consisting of F, Cl, CH3, CHF2, CF3, OCH3, OCHF2, OCF3, SCF3, and CN; or two adjacent hydrogen atoms can be replaced by a moiety -OCH2O-. In certain embodiments, the aryl group is phenyl or naphthyl. In certain other embodiments, the aryl group is phenyl.
[0384] "Cyano" and "nitrile" mean a -CN group.
[0385] "Cycloalkyl" means a 3- to 6-membered monocyclic ring. A cycloalkyl group may be saturated or unsaturated, but is not aromatic. Representative cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cyclohexenyl.
[0386] "Halo" or "halogen" means -Cl, -Br, -I or -F.
[0387] "Haloalkyl" means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
[0388] "Heteroaryl" means a monocyclic heteroaryl or bicyclic ring system containing at least one heteroaromatic ring. A monocyclic heteroaryl can be a 5- or 6-membered ring. A 5-membered ring consists of two double bonds and one, two, three, or four nitrogen atoms and optionally one oxygen or sulfur atom, or if present, the nitrogen atom may not be present. A 6-membered ring consists of three double bonds and one, two, three, or four nitrogen atoms. A 5- or 6-membered heteroaryl is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heteroaryl. Representative examples of monocyclic heteroaryls include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl. Bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl ring, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The fused cycloalkyl or heterocyclyl moiety of the bicyclic heteroaryl is optionally substituted with one or two groups that are independently oxo or thio. When the bicyclic heteroaryl contains a fused cycloalkyl, cycloalkenyl, or heterocyclyl ring, the bicyclic heteroaryl is connected to the parent molecular moiety through any carbon or nitrogen atom contained within the monocyclic heteroaryl moiety of the bicyclic system. When the bicyclic heteroaryl is a monocyclic heteroaryl fused to a phenyl ring, the bicyclic heteroaryl is connected to the parent molecular moiety through any carbon atom or nitrogen atom within the bicyclic system. Representative examples of bicyclic heteroaryl include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxadiazolyl, benzothiadiazolyl, benzothiazolyl, cinnolinyl, 5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-1-yl, furopyridinyl, indazolyl, indolyl, isoquinolinyl, naphthyridinyl, quinolinyl, purinyl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6,7,8-tetrahydroquinolin-3-yl, 5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl, thienopyridinyl, and 4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazolyl. In certain embodiments, the fused bicyclic heteroaryl is a 5- or 6-membered monocyclic heteroaryl ring fused to a benzene ring, a 5- or 6-membered monocyclic cycloalkyl, a 5- or 6-membered monocyclic cycloalkenyl, a 5- or 6-membered monocyclic heterocyclyl, or a 5- or 6-membered monocyclic heteroaryl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl are optionally substituted with one or two groups that are independently oxo or thio. In certain embodiments of the present disclosure, the heteroaryl is furanyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, thiazolyl, thienyl, triazolyl, benzimidazolyl, benzofuranyl, indazolyl, indolyl, quinolinyl, or the like. One or two hydrogen atoms as part of the heteroaryl may be replaced by a substituent selected from the group consisting of F, Cl, CH3, CHF2, CF3, OCH3, OCHF2, OCF3, SCF3, and CN.
[0389] "Heterocyclyl" means a monocyclic 4- to 7-membered heterocycle containing one or more heteroatoms independently selected from O, N, and S, wherein the ring is saturated or unsaturated, but not aromatic. Representative examples of monocyclic heterocycles include, but are not limited to, azetidinyl, hexahydroazepine, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, thiopyranyl. In certain embodiments, heterocyclyl is imidazolinyl, pyrrolidinyl, piperidinyl, or piperazinyl.
[0390] "Deuterated" means containing one or more carbon-deuterium bonds which replace a carbon-hydrogen bond, up to a maximum of all carbon-hydrogen bonds contained in the group under consideration.
[0391] The present invention is directed to novel HDAC6I of Formula I and Ib-Iqq and their uses in therapeutic treatments such as cancer, inflammation, traumatic brain injury, neurodegenerative disorders, nervous system diseases, peripheral neuropathy, stroke, hypertension, autoimmune diseases, inflammatory diseases, and malaria. The HDAC6I of the present invention also increases the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and / or chemotherapy. In some embodiments, the HDAC6I of the present invention selectively inhibits HDAC6 relative to other HDAC isozymes.
[0392] The present invention has been described in conjunction with preferred embodiments. However, it should be understood that the present invention is not limited to the disclosed embodiments. It should be understood that various modifications may be made by those skilled in the art in view of the description of the embodiments of the present invention herein. Such modifications are encompassed by the following claims.
[0393] The term "disease or condition in which HDAC inhibition would provide a benefit" relates to conditions in which HDACs and / or the effects of HDACs are important or necessary, e.g., for the onset, progression, expression of the disease or condition, or which are known to be treated by HDAC inhibitors (e.g., TSA, pivaloyloxymethylbutane (AN-9; Pivanex), FK-228 (Depsipeptide), PXD-101, NVP-LAQ824, SAHA, MS-275 and / or MGCD0103). Examples of such disorders include, but are not limited to, cancer, psoriasis, fibroproliferative disorders (e.g., liver fibrosis), smooth muscle proliferative disorders (e.g., atherosclerosis, restenosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar degeneration, Rett syndrome), peripheral neuropathies (Charcot-Marie-Tooth disease, giant axonal neuropathy (GAN)), inflammatory diseases (e.g., osteoarthritis, rheumatoid arthritis, colitis), diseases involving angiogenesis (e.g., cancer, rheumatoid arthritis, psoriasis, diabetic retinopathy), hematopoietic disorders (e.g., anemia, sickle cell anemia, thalassemia), fungal infections, parasitic infections (e.g., malaria, trypanosomiasis, helminthiasis, protozoal infections), bacterial infections, viral infections, and disorders treatable by immunomodulation (e.g., multiple sclerosis, autoimmune diabetes, lupus, atopic dermatitis, allergies, asthma, allergic rhinitis, inflammatory bowel disease; and for improved transplantation of grafts). One of ordinary skill in the art can readily determine whether a compound treats a disease or condition mediated by HDACs in any particular cell type, for example, by using assays that are readily available to assess the activity of a particular compound.
[0394] The term "second therapeutic agent" refers to a therapeutic agent that is different from the HDAC6I of the present invention and is known to treat the disease or condition of interest. For example, when cancer is the disease or condition of interest, the second therapeutic agent can be a known chemotherapeutic drug, such as paclitaxel or radiation.
[0395] The term "HDAC" refers to a family of enzymes that remove acetyl groups from proteins (e.g., the epsilon-amino group of lysine residues at the N-terminus of histones). The HDAC can be a human HDAC, including HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, and HDAC11. HDACs can also be derived from protozoa or fungi.
[0396] The terms "treat / treating / treatment" and the like refer to eliminating, reducing, alleviating, reversing and / or improving a disease or illness and / or the symptoms associated therewith. Although not excluded, treating a disease or illness does not require the complete elimination of the disease, illness or the symptoms associated therewith, including the treatment of acute or chronic signs, symptoms and / or dysfunction. As used herein, the terms "treat / treating / treatment" and the like may include "preventative treatment," which refers to reducing the probability of recurrence of a disease or illness or a previously controlled disease or illness in a subject who does not suffer from the disease or illness or the recurrence of the disease or illness, but has the risk of development or redevelopment or is prone to development or redevelopment. Therefore, "treatment" also includes relapse prevention or stage prevention. The terms "treatment" and synonyms encompass administering a therapeutically effective amount of a compound of the present invention to an individual in need of such treatment. Treatment can be directed according to symptoms, such as suppressing symptoms. It can take effect in the short term, can be directed in the medium term, or can be a long-term treatment, such as in the context of maintenance therapy.
[0397] As used herein, the term "therapeutically effective amount" or "effective dose" refers to the amount of an active ingredient that, when administered, is sufficient to effectively deliver the active ingredient to treat the disorder or disease of interest in an individual in need thereof. In the case of cancer or other proliferative disorders, a therapeutically effective amount of an agent can reduce (i.e., delay and preferably stop to some extent) unwanted cell proliferation; reduce the number of cancer cells; reduce the size of a tumor; inhibit (i.e., delay and preferably stop to some extent) cancer cell infiltration into peripheral organs; inhibit (i.e., delay and preferably stop to some extent) tumor metastasis; inhibit tumor growth to some extent; reduce HDAC signaling in target cells; and / or alleviate one or more symptoms associated with cancer to some extent. Insofar as the compound or composition administered prevents growth and / or kills existing cancer cells, it can be cytostatic and / or cytotoxic.
[0398] "Administered in parallel," "administered in combination," "administered simultaneously," and similar phrases mean that two or more agents are administered in parallel to a subject being treated. "In parallel" means that each agent is administered simultaneously or sequentially in any order at different time points. However, if not administered simultaneously, it means that they are administered to an individual in a certain order and are close enough in time to provide the desired therapeutic effect and can act synergistically. For example, HDAC6I of the present invention can be administered simultaneously as a second therapeutic agent, or sequentially in any order at different time points. HDAC6I of the present invention and the second therapeutic agent can be administered separately in any appropriate form and by any suitable route. When HDAC6I of the present invention and the second therapeutic agent are not administered in parallel, it should be understood that they can be administered to a subject in need in any order. For example, an HDAC6I of the present invention can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or after (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapeutic treatment modality (e.g., radiation therapy) to an individual in need thereof. In various embodiments, the HDAC6I of the present invention and the second therapeutic agent are administered at intervals of 1 minute, 10 minutes, 30 minutes, less than 1 hour, 1 hour, 1 to 2 hours, 2 to 3 hours, 3 to 4 hours, 4 to 5 hours, 5 to 6 hours, 6 to 7 hours, 7 to 8 hours, 8 to 9 hours, 9 to 10 hours, 10 to 11 hours, 11 to 12 hours, no more than 24 hours, or no more than 48 hours. In one embodiment, the components of the combination therapy are administered at intervals of 1 minute to 24 hours.
[0399] Unless otherwise indicated, otherwise in the context of describing the present invention (especially in the context of claims), the use of term "a / an", "said" and similar indicators should be interpreted as covering both singular and plural. Unless otherwise indicated herein, the statement of value range herein is merely used as a shorthand method for individually referring to each individual value belonging to the scope, and each individual value and sub-range is generally incorporated into this specification as if it were individually stated herein. The use of any and all examples or exemplary language (for example, "such as" and "as") provided herein is intended to better illustrate the present invention, and unless otherwise claimed, the scope of the present invention will not be limited. The language in this specification should not be interpreted as indicating any non-claimed element as necessary for practicing the present invention.
[0400] Example
[0401] Having now generally described the invention, the invention will be more readily understood by reference to the following examples, which are included merely to illustrate certain aspects and embodiments of the invention and are not intended to limit the invention.
[0402] Example 1: Synthesis of Exemplary Compounds of the Disclosure
[0403] Synthetic methods and procedures
[0404] The central (hetero)aromatic linker moiety is commercially available in a variety of structural modifications, such as:
[0405]
[0406] Carboxylic acids, their methyl esters and their nitriles can also be converted into each other by standard synthetic methods, or can be obtained from (hetero)aryl halides by transition metal catalyzed cyanation. Brominated building blocks can be used to modify these linker moieties by organometallic reactions, particularly transition metal catalyzed coupling reactions, in the later stages of the synthesis. For simplicity, the building blocks drawn below do not have the substituent R2. For intermediates with these substituents, similar reactions are used.
[0407] To prepare 1,3,4-oxadiazoles, hydrazides are obtained from carboxylic acid esters by hydrazinolysis, or from free carboxylic acids by coupling with protected hydrazines in the presence of amide / peptide coupling reagents (e.g., carbodiimide-type), preferably with the addition of an activating agent such as 4-(dimethylamino)pyridine (DMAP). Protective groups for hydrazines include, for example, tert-butyloxycarbonyl (Boc), which is subsequently removed by mild acid treatment, for example, by heating in hexafluoroisopropanol as a solvent; or benzyloxycarbonyl (Cbz), which can be removed under a variety of conditions, including catalytic hydrogenolysis over a Pd catalyst. The NH2 group of the hydrazide is then acylated with difluoroacetic anhydride or trifluoroacetic anhydride in the presence of a weak base. The resulting mixed 1,2-diacylhydrazines can be isolated and dehydrated to the desired 1,3,4-oxadiazole in a separate step (e.g., with trifluoromethanesulfonic anhydride and a base, or with CBr4 / PPh3), or more conveniently, dehydrated by an excess of the acylation mixture under the conditions of their formation.
[0408]
[0409] To prepare 1,2,4-oxadiazoles with a fluoroalkyl group at the 5-position, the nitrile is converted to an amidoxime with hydroxylamine. The amidoxime is N-acylated with difluoroacetic anhydride or trifluoroacetic anhydride in the presence of a weak base. An excess of the acylation mixture is used to cause the acylated amidoxime to dehydrate concomitantly with its formation, yielding a 3-(hetero)aryl-5-(difluoromethyl or trifluoromethyl)-1,2,4-oxadiazole.
[0410]
[0411] The reverse substitution pattern in the 1,2,4-oxadiazole series (i.e., a fluorinated alkyl group at the 3-position and a (hetero)aryl group at the 5-position) can be obtained from N-acylated difluoroacetamide oxime and trifluoroacetamide oxime. Trifluoroacetamide oxime is commercially available and can be N-acylated with a (hetero)aroyl halide in the presence of a weak base (e.g., pyridine) or with a carboxylic acid in the presence of an amide / peptide coupling reagent. If cyclization of the resulting intermediate does not occur spontaneously, it can be achieved using a dehydrating agent (e.g., trifluoroacetic anhydride / base).
[0412]
[0413] To prepare analogous difluoromethylated 1,2,4-oxadiazoles, it may be advantageous to proceed via 3-carboxaldehyde as an intermediate, followed by deoxyfluorination with reagents commonly used for this purpose, such as sulfur tetrafluoride, diethylaminosulfur trifluoride (DAST), bis(2-methoxyethyl)aminosulfur trifluoride or N,N-diethyl-S,S-difluorosulfonium tetrafluoroborate 3-Formaldehydes are obtained from their diethyl acetals in a similar sequence to the one described above, starting with 2,2-diethoxyacetamide oxime. This building block is in turn formed by adding hydroxylamine to diethoxyacetonitrile, a commercially available liquid that is more convenient to handle than the gaseous difluoroacetonitrile required for the preparation of difluoroacetamide oxime.
[0414]
[0415] Oxazole is very common in heterocyclic chemistry and can be prepared by a variety of methods. The classic Robinson-Gabriel method consists of dehydration of 2-(acylamino)ketones and can be used to prepare certain compounds of the present invention, wherein the (hetero)aryl group is attached to the 5-position of the oxazole ring. Many dehydrating agents (such as those given below) can affect this conversion. Acylaminoketones are prepared by N-acylation of aminoketones, for example, in the form of their stable salts (such as hydrochlorides). Aminoketone salts can be prepared by a two-step procedure containing a nitrile containing the necessary linker (hetero) aromatic ring, which consists of adding a Grignard reagent to form an imine, followed by Neber rearrangement (Baumgarten, HE et al., J.Org.Chem.1963,28,2369).
[0416]
[0417] 2-(Acylamino)ketone intermediates can also be obtained from diazoketones by Rh-catalyzed carbene formation and insertion into the NH bond of a primary carboxamide (in this case, difluoroacetamide or trifluoroacetamide) (Davies, JR et al. Tetrahedron 2004, 60, 3967). Diazoketones can be synthesized from diazoalkanes and their derivatives by acylation with acyl halides in the presence of a weak base.
[0418] Oxazole can be brominated at the 4-position with NBS in acetone (Khan, AH; Chen, JS Org. Lett. 2015, 17, 3718). The 4-bromide is a useful derivative for the introduction of various substituents via transition metal-catalyzed displacement and coupling reactions, for example, trifluoromethylation via Cu-catalyzed reaction with methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (Chen, QY; Wu, SW J Chem. Soc., Chem. Commun. 1989, 705; Clarke, SL; McGlacken, GP Chem. Eur. J. 2017, 23, 1219). Methylation can be achieved by Stille coupling with Me4Sn; cyanation can be achieved by various schemes using cyanide anions or various sources thereof, usually under Cu or Pd catalysis (e.g., Ren, Y. et al. Tetrahedron Lett. 2009, 50, 4595); fluorination can be achieved by Br-F exchange under Pd catalysis (Lee, HG et al. J. Am. Chem. Soc. 2014, 136, 3792); and chlorination can be achieved by Br-Cl exchange under Cu catalysis (Feng, X. et al. Chem. Commun. 2012, 48, 9468). The 4-nitrile produced by cyanation can be reduced to an aldehyde, for example, with diisobutylaluminum hydride, which is a precursor of 4-(difluoromethyl)oxazole generated by deoxyfluorination (DAST, etc.).
[0419]
[0420] For example, by a recently reported oxidation procedure (Xiao, F. Org. Lett. 2019, 21, 8533), isomeric oxazoles of the previous series (i.e., (hetero)aryl groups are attached to the 4-position of the ring) can be obtained from (hetero)aryl methyl ketones. These starting materials can be prepared from carboxylic acids by reaction of their derived Weinreb amides with methylmagnesium halides, or (not shown) by applying the same reagents to nitriles followed by imine hydrolysis; some (e.g., 5-acetyl-2-methylpyridine) are commercially available. The described scheme places an arylthio substituent at the 5-position, which is removed by standard desulfurization with Raney nickel or nickel boride.
[0421]
[0422] Following assembly of the linker / zinc-binding group moiety, the methyl group attached to the six-membered ring needs to be converted into an alkylating agent. This can be achieved via free radical bromination. The brominating agent is typically N-bromosuccinimide (NBS) or 1,3-dibromo-5,5-dimethylhydantoin, and the free radical initiator is an azo compound such as azobis(isobutyronitrile) (AIBN), or a peroxide such as dibenzoyl peroxide. These initiators are widely used for reactions carried out at the boiling temperature (77°C) of carbon tetrachloride (the traditionally preferred solvent), where they have a suitable decomposition rate. In the present work, this environmentally harmful solvent has been replaced by fluorobenzene, a non-polar solvent with low reactivity and a similar boiling point (85°C). Photochemical initiation is also possible. In addition to the desired monobrominated product, unreacted starting material and dibrominated products are also encountered. These can usually be easily separated by normal phase column chromatography. The dibrominated product can be recycled to the starting material by free radical (e.g., Bu3SnH or H3PO2 / AIBN) or catalytic (e.g., H2, Pd / C) hydrodebromination.
[0423]
[0424] The sultam building blocks and the above-mentioned alkylating agents are joined together by reaction in a dipolar aprotic solvent (eg DMF) in the presence of a weak base. The following paragraphs disclose a method for preparing the necessary sultams.
[0425] 3,4-Dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide and certain derivatives can be obtained by a literature procedure (Moroda, A.; Togo, H. Synthesis 2008, 1257) starting from 2-arylethanesulfonyl chloride. Tolerable substituents include halo and alkyl groups. Although unsubstituted sulfonyl chlorides are commercially available, certain derivatives need to be synthesized, for example, via the sequence depicted. Final reductive cleavage of the N-O bond can be achieved by a variety of methods, such as reduction with SmI2, catalytic hydrogenolysis, dissolved metal reduction schemes, and electrochemical methods. Occasional cleavage has also been observed during the execution of certain other transformations.
[0426]
[0427] Substituents at the ortho and para positions in 2-arylethanesulfonyl chlorides clearly yield 5- and 7-substituted 3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxides, respectively, while meta substituents can produce mixtures of 6- and 8-substituted compounds that require separation. A preferred entry in the 6-substituted series is an electrophilic substitution on an intermediate lacking a 6-substituent, in which the nitrogen atom exerts a predominantly or exclusively para-positioning influence. An example is the 6-bromination of an N-methoxy precursor or free sultam in the parent series (all R1 = H) with N-bromosuccinimide (NBS).
[0428]
[0429] The same general sequence applies to compounds in which aliphatic carbon atoms bear substituents. For example, the desired substituted phenylethanol can be obtained by reducing substituted phenylacetic acids or their esters. The latter can be synthesized, for example, by alkylation of ester enolates or by arylation thereof under transition metal catalysis. An example is shown below in which the ester enolate is a zinc enolate formed by the Reformatsky reaction of the corresponding α-bromoester with Zn metal, and the arylation step is a Negishi coupling reaction (Sakuma, D. et al. Chem. Lett. 2015, 44, 818).
[0430]
[0431] 3,4-Dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxides bearing halogen substituents (e.g., Cl and Br) on the aromatic ring are suitable starting materials for the introduction of other substituents via transition-metal-catalyzed exchange and coupling reactions. This approach is illustrated by the Suzuki coupling reaction between 3,4-dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide and an arylboronic acid, where the primary product is not a simple coupling product but rather a coupling product with concomitant reductive cleavage of the N-O bond. Other possibilities include, but are not limited to, halogen-halogen exchange, alkoxylation, amination, amidation, trifluoromethylation, trifluoromethylthioation, cyanation, and carbonylation reactions, as well as Heck, Kumada, Negishi, Sonogashira, and Stille coupling reactions. Such reactions have received significant attention in modern synthetic methodology research and are familiar to those skilled in the art.
[0432] 3,4-Dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxides bearing halogen substituents (e.g., Cl and Br) on the aromatic ring are suitable starting materials for the introduction of other substituents via transition-metal-catalyzed exchange and coupling reactions. This approach is illustrated by the Suzuki coupling reaction between 3,4-dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide and an arylboronic acid, where the primary product is not a simple coupling product but rather a coupling product with concomitant reductive cleavage of the N-O bond. Other possibilities include, but are not limited to, halogen-halogen exchange, alkoxylation, amination, amidation, trifluoromethylation, trifluoromethylthioation, cyanation, and carbonylation reactions, as well as Heck, Kumada, Negishi, Sonogashira, and Stille coupling reactions. Such reactions have received significant attention in modern synthetic methodology research and are familiar to those skilled in the art.
[0433]
[0434] If neither 1-methoxysultam nor the corresponding free sultam is suitable for the desired reaction, for example due to premature loss of the 1-methoxy group or due to limited acidity or solubility of the NH of the free sultam, various N-protecting groups can be introduced and later removed when no longer needed. An example is the methoxymethyl group, which can be introduced under mild alkylation conditions and removed by treatment with acid. Other suitable protecting groups include, but are not limited to, benzyloxymethyl, which provides an additional option for hydrogenolytic cleavage; silyl groups such as tert-butyldimethylsilyl, tert-butyldiphenylsilyl, and triisopropylsilyl, which are removed by treatment with acid, protic base, or fluoride anion; benzyl and benzyloxycarbonyl, which are removed by hydrogenolysis; tert-butyloxycarbonyl, which is removed with acid; and 4-methoxybenzyl and 2,4-dimethoxybenzyl, which are removed by oxidation or by treatment with strong acid.
[0435]
[0436] 4-Keto-derivatives (i.e., 1H-benzo[c][1,2]thiazin-4(3H)-one 2,2-dioxide) can be synthesized according to the following scheme, which is similar to the work of Shafiq, M. et al. J. Chil. Chem. Soc. 2011, 56, 527, in which N-Boc replaces N-Me to replace the N-unsubstituted sultam.
[0437]
[0438] Another method for preparing 1H-benzo[c][1,2]thiazin-4(3H)-one 2,2-dioxide involves N-sulfonylation of aniline with methoxycarbonylmethanesulfonyl chloride. After ester hydrolysis, the carboxylic acid is cyclized in an intramolecular Friedel-Crafts acylation reaction (Pasteris, RJ US 4867781, September 19, 1989; Nie, H.; Widdowson, KL US 6436927, August 20, 2002).
[0439]
[0440] 1H-Benzo[c][1,2]thiazin-4(3H)-one 2,2-dioxide reacts with tosylhydrazine to form tosylhydrazone, which is reduced with catecholborane to form an alternative synthesis of 3,4-dihydro-1H-benzo[c][1,2]thiazine 2,2-dioxide (Pasteris, RJUS4867781, September 19, 1989). After treatment with base, the tosylhydrazone undergoes a Bamford-Stevens reaction to provide 1H-benzo[c][1,2]thiazine 2,2-dioxide (Nie, H.; Widdowson, KLUS6436927, August 20, 2002).
[0441]
[0442] The reaction of o-phenylenediamine, o-aminophenol, and o-mercaptoaniline with chloromethanesulfonyl chloride in the presence of a base can yield a sultam structural unit containing a heteroatom at position 4. In the case where X = NH, oxidation with MnO2 yields the corresponding unsaturated heterocycle (Nie, H.; Widdowson, KL US 6436927, August 20, 2002).
[0443]
[0444] Heating 2-aminobenzylamine with a sulfonamide in pyridine forms 3,4-dihydro-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxide (CN1909909B, December 15, 2010). One way to synthesize the necessary diamine intermediate is by forming an oxime from a 2-nitrophenyl alkyl ketone, followed by reduction, for example, by catalytic hydrogenation.
[0445]
[0446] Up to this point, the compounds of the present invention have been synthesized by first building a zinc-bound fluoroalkylated oxadiazole or oxazole moiety onto a linker ring and then attaching this assembly to a sultam capping group. It is also possible to first attach the capping group to the linker and then build the fluoroalkylated oxadiazole or oxazole moiety onto the assembly using the same type of reaction as in the first disclosed method. Potential functional group incompatibilities can be remedied by using appropriate protecting groups or by generating interfering functional groups from less reactive precursors (e.g., aromatic bromides) in subsequent steps through reactions such as displacement or coupling reactions.
[0447]
[0448] The following synthetic scheme represents the reactions used to synthesize HDAC6I of the present invention. Modifications and alternative schemes for preparing HDAC6I of the present invention are readily within the capabilities of those skilled in the art.
[0449] All starting materials and solvents were purchased from commercial suppliers at reagent purity and used as received without further purification. Reactions were monitored by thin-layer chromatography on silica gel-coated glass plates, visualized at 254 nm and / or using appropriate stains. Spectra were recorded at 400 or 500 MHz on Bruker Avance-400 and Avance-500 spectrometers, respectively. 1 H NMR spectra. Chemical shifts (δ scale) are reported in parts per million (ppm) relative to TMS (in CDCl3) or relative to the solvent signal (in DMSO-d6; the solvent signal is set at δ 2.50). Signal characteristics are: s (singlet), d (doublet), t (triplet), m (multiplet), and br (broad peak).
[0450] Compound 1. 1-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl]methyl]-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0451] N-(6-Methylnicotinoyl)hydrazine
[0452]
[0453] In a 500 mL round bottom flask equipped with a stirring bar, heating mantle, reflux condenser and Ar balloon, a mixture of methyl 6-methylnicotinate (7.39 g, 48.9 mmol), 1-propanol (60 mL) and hydrazine monohydrate (9.5 mL, 195 mmol, 4.0 equiv.) was heated to reflux for 22 h. TLC analysis (SiO2, MeOH / CHCl3) showed that R fThe only significant component was approximately 0.25 hydrazide. The mixture was evaporated and the residue was dissolved in MeOH and adsorbed on SiO2 (50 g). The residue was chromatographed on SiO2 (15 x 6 cm) using MeOH / CH2Cl2 1:9 as the starting material, followed by MeOH / CH2Cl2 15:85. When hydrazide appeared in the eluent, the mixing ratio was further changed to 1:4. The eluent containing the product was concentrated to a small volume and added (50 mL) to ensure complete removal of MeOH. The evaporation was completed and the residue was dried under vacuum to yield 6.83 g (92%) of colorless solid. 1 HNMR (400 MHz, DMSO-d6) δ9.86 (s, 1H), 8.84 (narrow m, 1H), 8.04 (dd, 1H, J = 8.1, 2.4 Hz), 7.33 (d, 1H, J = 8.1 Hz), 4.52 (s, 2H); CH3 was obscured by the DMSO-d5 signal. 1 H NMR (400 MHz, D2O) δ 8.69 (narrow m, 1H), 8.02 (dd, 1H, J = 8.2, 2.4 Hz), 7.41 (d, 1H, J = 8.2 Hz), 2.56 (s, 3H).
[0454] 5-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-methylpyridine
[0455]
[0456] In a 500 mL round-bottom flask equipped with a stir bar, dropping funnel, and balloon was placed N-(6-methylnicotinoyl)hydrazine (6.83 g, 45.2 mmol), anhydrous CH2Cl2 (80 mL), and triethylamine (31.5 mL, 226 mmol, 5.0 equiv.). The suspension was cooled in an ice bath, and difluoroacetic anhydride (16.0 mL, 136 mL, 3.0 equiv.) was added dropwise over 45 min. The starting material dissolved quickly. The solution was stirred at ambient temperature for 22.5 h, and it became very dark. TLC (SiO2, EtOAc / hexane 1:1) showed R fApproximately 0.35% product, along with a diffuse polar tail and brown baseline spots. Water (10 mL) was added dropwise under water cooling over 20 min, followed by a solution of citric acid (17.3 g, 90 mmol, 2.0 equiv.) in water (40 mL). The pH of the aqueous phase was approximately 3.5. The phases were separated and the aqueous phase was extracted sequentially with CHCl and EtOAc (50 mL each). The combined organic phases were washed with brine (50 mL; organic phase = lower layer) and evaporated, leaving a dark brown oil that was chromatographed on SiO (20 x 5 cm, EtOAc / hexane 1:1). Most of the initial distillate (not visible on bulk TLC) was removed, but some of the polar tail remained in the product. After evaporation, 6.9 g of a brown oil remained, which solidified upon standing. This crude material was subjected to two bulb-to-bulb distillations (105-125° C. / oil pump vacuum) to afford 6.17 g of a mixture of colorless crystals and a yellow oil. The distillate was dissolved in MeOH (20 mL) and the solution placed in the freezer. Initially, no crystallization occurred. One drop of solution was allowed to evaporate, on which crystals formed. These crystals were used to seed the remaining solution, from which the product rapidly crystallized. After an additional 3 h in the freezer, the product was isolated by suction filtration, washed with cold MeOH (10 mL), and dried under vacuum to yield 3.77 g (40%) of colorless crystals contaminated with approximately 3 mol % of difluoroacetic acid (according to 1 1H NMR). 1 H NMR (CDCl3, 400 MHz) δ 9.22 (narrow m, 1H), 8.29 (dd, 1H, J = 8.2, 2.3 Hz), 7.37 (d, 1H, J = 8.2 Hz), 6.95 (t, 1H, J H-F =51.7Hz),2.69(s,3H); difluoroacetic acid at δ5.97(t,1H,J H-F =54.7Hz). 13 C NMR(CDCl3,100MHz)δ164.44,163.27,158.32(t,J C-F =29.2Hz),147.77,134.85,123.61,116.48,105.68(t,J C-F =241.2Hz),24.79.
[0457] The mother liquor contained a large amount of difluoroacetic acid (by NMR). It was evaporated and dissolved in fresh MeOH (30 mL). Amberlite IRA-67 (weakly basic anion exchange resin, free base; Sigma No. A9960; CAS Reg. No. 65899-87-7; 4 g) was added. The mixture was vortexed from time to time for 50 min. The resin was removed by suction filtration and washed with MeOH (3x5 mL).1 An aliquot of the filtrate was analyzed by H NMR and a small concentration of difluoroacetic acid was found to persist. The treatment with anion exchange resin (2 g) was repeated for 5.7 h. After filtration from the resin, the filtrate was adsorbed on SiO2 (8 g). The filtrate was concentrated on SiO2 (19 x 3.8 cm, t-BuOMe; TLC, R f The residue was chromatographed on a 50 mL flask (0.5 mL, slightly streaky) to remove some polar material. The eluent was evaporated and dried under vacuum to yield an additional 1.24 g (13%) of the oxadiazole as slightly yellow crystals.
[0458] 2-(Bromomethyl)-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridine
[0459]
[0460] In a 250 mL, three-necked flask equipped with a stir bar, heating mantle, stopper, reflux condenser (connected to an Ar balloon), and a septum-filled dropping funnel were placed 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-methylpyridine (3.75 g, 17.8 mmol), 1,3-dibromo-5,5-dimethylhydantoin (2.78 g, 9.8 mmol, 0.55 equiv.), and fluorobenzene (50 mL). The atmosphere was replaced with Ar. The dropping funnel was charged with a solution of azobis(isobutyronitrile) (AIBN; 0.44 g, 2.7 mmol, 0.15 equiv.) in fluorobenzene (5 mL), of which approximately 20% was added to the reaction mixture. The mixture was heated to reflux, and the remaining AIBN solution was added in small portions over the course of 1 h. At this point, most of the temporarily formed Br2 had faded. Reflux was continued for 10 min, and the mixture was cooled to ambient temperature. TLC (SiO2, EtOAc / hexane 2:3) showed R f The three main components are approximately 0.75, 0.5 and 0.3, corresponding to the dibrominated by-product, the desired monobrominated product and the starting material, respectively. The dark solution is filtered out from the precipitated hydantoin by diatomaceous earth suction, and fluorobenzene is recovered by rotary evaporation. The hydantoin is washed with the recovered fluorobenzene, and the combined liquid is evaporated again. The residue is chromatographed on SiO2 (29x 5cm, EtOAc / hexane is 1:3 for the dibromide, 1:2 for the monobromide, and 3:2 for the starting material). Evaporation of the appropriate fractions produces 1.34g (semi-solid; 20%) of the dibromide, 2.55g (off-white solid; 49%) of the monobromide and 1.07g (light amber solid, 29%) of the starting material. Monobromide: 1H NMR (400 MHz, CDCl3) δ 9.29 (narrow m, 1H), 8.42 (dd, 1H, J = 8.2, 2.2 Hz), 7.66 (dd, 1H, J = 8.2, 0.4 Hz), 6.95 (t, 1H, J H-F =51.6Hz),4.62(s,2H).
[0461] N-Methoxy-2-phenylethanesulfonamide
[0462]
[0463] In a 250 mL round-bottom flask equipped with a stirring bar and a dropping funnel, O-methylhydroxylamine hydrochloride (5.2 g, 62 mmol, 2.2 equiv.) was suspended in CH3CN (40 mL). The mixture was cooled in an ice bath, and a solution of NaOH (2.5 g, 62 mmol, 2.2 equiv.) in water (15 mL) was added dropwise over 10 min. After a further 25 min at 0°C, the dropping funnel was replaced with a dry one, and a solution of 2-phenylethanesulfonyl chloride (5.75 g, 28.1 mmol) in anhydrous CH3CN (20 mL) was added dropwise over 15 min. Stirring was continued in the ice bath for 20 min, followed by stirring at ambient temperature for 22 h. After partial evaporation to remove the organic solvent (foaming!), water (80 mL) was added, and the product was extracted into EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 (20 g) and evaporated, and the residue was dried under vacuum to yield 5.93 g (98%) of the sulfonamide as a colorless solid. 1 HNMR (CDCl3, 400MHz) δ7.37-7.32 (m, 1H), 7.31-7.23 (m, 3H), 6.63 (br s, 1H), 3.77 (s, 3H), 3.51, 3.13 (AA'XX' multiplets, slightly broadened high field, 4H, J AX +J AX' =15.6Hz).
[0464] 3,4-Dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0465]
[0466] In a 500 mL round-bottom flask with a stir bar, O-methoxy-2-phenylethanesulfonamide (5.98 g, 27.8 mmol) was dissolved in 2,2,2-trifluoroethanol (83 mL) under gentle heating. Iodobenzene (0.31 mL, 2.8 mmol, 0.10 equiv.) was added. Meta-chloroperbenzoic acid (75%, the remainder being meta-chlorobenzoic acid and water; 7.05 g, 30.6 mmol, 1.1 equiv.) was added portionwise over 10 min, resulting in a mild exotherm. The flask was loosely stoppered, and the mixture was stirred for 4 h without temperature control. Early on, the peroxyacid went into solution; later, a pale yellow, then brown, suspension formed. Shortly before quenching, TLC analysis (SiO2, EtOAc / toluene 1:9) showed R f The product of about 0.5, iodobenzene, baseline material and polarity stripe near solvent front.With mixture and Na SO (2.5g, 20mmol) solution in water (50mL) is stirred 25min under rt.Leave most of solid residue after organic solvent evaporation (boiling!), be dissolved in EtOAc (50mL) and salt solution (30mL).Separate each phase (slightly slow but complete), and use EtOAc (2x 50mL) aqueous phase extraction.Through Na SO (20g) dry light yellow organic phase of merging and be evaporated to near drying.Residual oily matter is dissolved among the MeOH (50mL), then rapid crystallization occurs.After standing overnight in refrigerator, by suction filtration separation precipitate, with cold MeOH (2x 10mL) washing, and dry under vacuum, generate 4.25g colorless crystals. The mother liquor still contained product, in addition to polar and nonpolar impurities, by TLC and was adsorbed onto SiO (5 g). The residue was chromatographed on SiO (20 x 4 cm, EtOAc / toluene 1:19, then 1:9), evaporated, and dried under vacuum to yield an additional 0.90 g of the cyclized product as a colorless solid. Total yield: 5.15 g (87%). 1 H NMR (CDCl 3 , 400 MHz) δ 7.40-7.36 (m, 1H), 7.36-7.29 (m, 2H), 7.23-7.19 (m, 1H), 4.08 (s, 3H), 3.50, 3.42 (AA'BB' multiplet, slightly broadened high field portion, 4H).
[0467] 3,4-Dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0468]
[0469] A 250 mL round bottom flask with a stir bar was charged with 3,4-dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide (2.05 g, 9.61 mmol), p-toluenesulfonic acid monohydrate (1.83 g, 9.6 mmol), 20% Pd(OH)2 / C (50% H2O; Alfa Aesar No. 42578; 0.22 g), THF (20 mL) and EtOH (undenatured, 40 mL). A H2 balloon was placed on the flask via a three-way stopcock, and the flask was evacuated and flushed with H2 three times. The hydrogenation was allowed to proceed at rt for 6.5 h, followed by replacement of the H2 atmosphere with Ar. TLC analysis (SiO2, EtOAc / hexane 1:1) showed a single spot of the product (R f About 0.6), the product and the starting material (R f The mixture was adsorbed onto SiO2 (12 g) and the residue was filtered through SiO2 (12 x 3 cm, EtOAc / hexane 43:57). The eluent containing the product was contaminated with some baseline material and provided a pink semisolid upon evaporation. This material was evaporated with MeOH to give a crystalline solid which was dissolved in tert-butyl methyl ether. Filtration with suction, repeated washing with tert-butyl methyl ether and drying under vacuum gave 1.27 g (72%) of the product as an off-white powder with a purity (measured by 1 H NMR) was sufficient for use in the subsequent step. 1 HNMR (DMSO-d6, 400 MHz) δ 10.09 (s, 1H), 7.19 (d, 1H, J = 7.4 Hz), 7.16 (t with unresolved long-range coupling, 1H, J = 7.5 Hz), 6.96 (dt, 1H, J = 1.1 Hz (d), 7.5 Hz (t)), 6.76 (dd, 1H, J = 8.0, 0.8 Hz), 3.36-3.27 (AA'BB' multiplet, 4H). 1 H NMR (CDCl3, 400 MHz) δ 7.23-7.16 (m, 2H), 7.05 (dt, 1H, J = 0.7 Hz (d), 7.5 Hz (t)), 6.75 (d, 1H, J = 8.0 Hz), 6.37 (br s, 1H), 3.49, 3.32 (AA'XX' multiplets, slightly broadened low field part, 4H, J AX +J AX' =13.5Hz).
[0470] 1-[[5-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl]methyl]-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0471]
[0472] In a 100 mL round-bottom flask with a stir bar was placed 3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide (615 mg, 3.36 mmol), 2-[6-(bromomethyl)pyridin-3-yl]-5-(difluoromethyl)-1,3,4-oxadiazole (1.022 g, 3.52 mmol, 1.05 equiv.), finely ground KCO (0.56 g, 4.05 mmol, 1.2 equiv.), KI (0.11 g, 0.67 mmol, 0.2 equiv.), and anhydrous DMF (10 mL). The flask was wrapped in Al foil to shield from light, and the mixture was stirred at ambient temperature for 19 h. Water (200 mL) and EtOAc / hexane 1:1 (100 mL, followed by 2 x 50 mL) were added, and the phases were separated. The combined organic phases were washed with water (200 mL) and brine (25 mL). TLC (SiO2, EtOAc / hexane 2:3) showed R f The product was about 0.3. The solution was adsorbed on SiO2 (10 g) and the material was chromatographed on SiO2 (9 x 5 cm, EtOAc / hexane 2:3). The fractions containing the product were evaporated and the residue was co-evaporated with CH3CN and dried under vacuum to give the product (1.28 g) as a colorless glass containing 2.4 wt% CH3CN (by 1 H NMR; corrected yield: 1.25 g, 95%). 1 H NMR (CDCl3, 400MHz) δ9.30 (narrow m, 1H), 8.37 (dd, 1H, J = 8.3, 2.2Hz), 7.75 (d, 1H, J = 8 .3Hz),7.19(d,1H,J=7.2Hz),7.13(dt,1H,J=1.2Hz(d),7.8Hz(t)),6.94(t,1H,J H-F =51.7 Hz), 6.79 (d, 1H, J=8.3 Hz), 5.23 (s, 2H), 3.56, 3.52 (AA'BB' multiplet, 4H).
[0473] Compound 9. 1-[[5-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl]methyl]-6-(4-fluorophenyl)-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0474] 6-Bromo-3,4-dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0475]
[0476] To a solution of 3,4-dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide (0.95 g, 4.45 mmol) in DMF (8 mL) was added N-bromosuccinimide (NBS; 0.79 g, 4.45 mmol) in one portion. The mixture was stirred at rt for 21 h. TLC (micro-aqueous treatment: water / EtOAc; SiO2, EtOAc / hexane 1:4) showed that the starting material (R f about 0.25) and the product (R f The bromination reaction was carried out for an additional 44 h. TLC indicated complete conversion. A solution of Na2SO3 (1 g) in water (20 mL) was added and the mixture was stirred at rt for 20 min. Water (80 mL) and EtOAc / hexane 1:1 (50 mL) were further added. The phases were separated and the aqueous phase was extracted with EtOAc / hexane 1:1 (20 mL). The combined organic phases were washed with water (2 x 100 mL), dried over Na2SO4 (5 g), and concentrated to near dryness. MeOH (5 mL) was added and the solution was placed in a freezer. Crystallization slowly occurred after scratching and was allowed to proceed for 2 days. The mother liquor was removed with a pipette and the solid was washed with cold MeOH (5 mL). Drying under vacuum yielded 0.84 g (65%) of a colorless material with a purity of 96% (by OMe 1 Integration of the H NMR signals). Evaporation of the mother liquor left an additional 0.33 g (25%) of a light amber glass, contaminated with traces of starting material (by TLC), but suitable for use in the Suzuki coupling reaction. 1 H NMR (CDCl3, 400 MHz) δ 7.44 (dd, 1H, J = 8.5, 2.1 Hz), 7.37 (narrow m, 1H), 7.24 (d, 1H, J = 8.6 Hz), 4.05 (s, 3H), 3.47, 3.37 (AA'XX' multiplet, 4H, J AX +J AX’ =13.0Hz).
[0477] 6-(4-Fluorophenyl)-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0478]
[0479] A resealable vial with a stir bar was charged with 6-bromo-3,4-dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide (332 mg, 1.14 mmol), 4-fluorophenylboronic acid (175 mg, 1.25 mmol, 1.1 equiv.), bis(dibenzylideneacetone)dipalladium(0) (14.5 mg, 16 μmol, 1.4%), tricyclohexylphosphine tetrafluoroborate (10.5 mg, 28 μmol, 2.5%), K 3 PO 4 (1.27 M aqueous solution; 1.5 mL, 1.9 mmol, 1.7 equiv.), and dioxane (3.0 mL). The mixture was purged with Ar, and the vial was capped and heated to 100° C. (oil bath temperature) for 24 h. TLC (SiO 2 , EtOAc / toluene 1:9) showed R f The main product is about 0.2 and R f Small spots of approximately 0.25 and 0.45 were observed. The phases were separated and the aqueous phase was extracted with EtOAc (2 x 3 mL). The mixture was adsorbed onto SiO2 (3 g). The residue was chromatographed on SiO2 (15 x 3 cm, EtOAc / toluene 1:9 to 1:6). The non-polar fraction (16 mg after evaporation) consisted primarily of the initially expected low-purity product 6-(4-fluorophenyl)-3,4-dihydro-1-methoxy-1H-benzo[c][1,2]thiazine-2,2-dioxide. 1 H NMR (CDCl3, 400 MHz) δ 7.49, 7.12 (AA'XX' multiplet with additional HF coupling, 4H), 7.44 (dd, 1H, J = 8.5, 2.1 Hz), 7.34 (d, 1H, J = 1.9 Hz), 7.03 (d, 1H, J = 8.5 Hz), 3.52, 3.38 (AA'XX' multiplet, 4H, J AX +J AX’ =13.8Hz),3.34(s,3H).
[0480] according to 1 H NMR spectrum showed that the major fraction consisted of two N-demethoxy compounds, one derived from the coupling product and one from the hydrodehalogenation product. This material, after recrystallization from ethanol (refluxed from ambient temperature to the refrigerator), yielded 98 mg of crystals, with the component ratio improved to 8:1. Further recrystallization from ethanol (same temperature interval) ultimately yielded 78 mg (25%) of the title compound as slightly yellowish, compact crystals. 1H NMR (DMSO-d6, 400 MHz) δ 10.23 (br s, 1H), 7.65, 7.26 (AA'XX' multiplet with additional HF coupling, 4H), 7.51 (d, 1H, J = 2.0 Hz), 7.46 (dd, 1H, J = 8.3, 2.1 Hz), 6.83 (d, 1H, J = 8.3 Hz), 3.38 (s, 4H).
[0481] 1-[[5-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl]methyl]-6-(4-fluorophenyl)-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0482]
[0483] In a 20 mL vial with a stir bar was placed 6-(4-fluorophenyl)-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide (76.5 mg, 276 μmol), 2-[6-(bromomethyl)pyridin-3-yl]-5-(difluoromethyl)-1,3,4-oxadiazole (88 mg, 303 μmol, 1.1 equiv.), finely ground KCO (48 mg, 0.35 mmol, 1.25 equiv.), KI (9 mg, 54 μmol, 0.2 equiv.), and anhydrous DMF (0.8 mL). The vial was wrapped in Al foil to shield from light, and the mixture was stirred at ambient temperature for 16.5 h. Water (25 mL) and EtOAc / hexane 1:1 (20 mL) were added, and the phases were separated. The aqueous phase was extracted with EtOAc / hexane 1:1 (10 mL) and the combined organic phases were washed with brine (10 mL). TLC (SiO2, EtOAc / hexane 2:3) showed R f Approximately 0.2% of product. The solution was adsorbed onto SiO2 (1 g) and the material was chromatographed on SiO2 (17 x 3 cm, EtOAc / hexane 2:3 then 1:1). The product-containing fractions were evaporated and dried under vacuum to give the product as an off-white solid (125 mg, 93%). 1 H NMR (CDCl3, 400 MHz) δ 9.32 (narrow m, 1H), 8.39 (dd, 1H, J = 8.2, 2.2 Hz), 7.76 (d, 1H, J = 8.2 Hz), 7.44, 7.10 (AA'XX' multiplet with additional HF coupling, 4H), 7.36 (narrow m, 1H), 7.30 (dd, 1H, J = 8.5, 1.9 Hz), 6.93 (t, 1H, J H-F=51.6 Hz), 6.87 (d, 1H, J=8.5 Hz), 5.26 (s, 2H), 3.63, 3.56 (AA'BB' multiplet, 4H).
[0484] Compound 15. 1-[[5-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl]methyl]-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0485] 1-(tert-Butyloxycarbonyl)-2-(2-methylpyrimidine-5-carbonyl)hydrazine
[0486]
[0487] 2-Methylpyrimidine-5-carboxylic acid (1.93 g, 14.0 mmol) and tert-butyl carbazate (2.22 g, 16.8 mmol) were dissolved in CHCl (50 mL). DMAP (2.22 g, 18.2 mmol, 1.3 equiv.) and EDCI·HCl (3.09 g, 16.1 g, 1.15 equiv.) were added. The flask was fitted with a balloon to exclude water, and the amber solution was magnetically stirred at rt for 70.5 h. TLC (SiO, EtOAc / CHCN 3:1) showed a single mobile UV absorbing product (R f The reaction mixture was adsorbed onto SiO2 (25 g) and the residue was filtered through SiO2 (9 cm L x 6 cm D, EtOAc / CH3CN 3:1; Note 1). The eluent was evaporated and the residue was dried under vacuum to give a colorless solid (3.15 g, 89%). 1 HNMR (CDCl3, 400 MHz) δ 9.02 (s, 2H), 8.42 (br, 1H), 6.77 (br, 1H), 2.81 (s, 3H), 1.50 (s, 9H). A prominent impurity exhibited a singlet peak for tert-butyl at δ 1.46.
[0488] Note 1. Due to the relatively high viscosity of the solvent, a column with good permeability is required to achieve a practical flow rate. In this case, the use of a reused dropping funnel resulted in elution lasting several days. A coarser silica grade than is typically used for flash chromatography may be advantageous.
[0489] Note 2. The methyl ester reacts with hydrazine hydrate in the same manner as described for the pyridine series to produce a mixture of products.
[0490] N-(2-Methylpyrimidine-5-carbonyl)hydrazine
[0491]
[0492] In a 250mL round-bottom flask with a stirring rod, a heating mantle, a reflux condenser and a balloon (for excluding moisture), a solution of 1-(tert-butyloxycarbonyl)-2-(2-methylpyrimidine-5-carbonyl)hydrazine (3.15g, 12.5mmol) in 1,1,1,3,3,3-hexafluoro-2-propanol (34mL) was heated to reflux for 38.5h. Most of the solvent was distilled off at atmospheric pressure. The residue began to solidify after cooling. EtOAc (30mL) was added and the mixture was stirred to crush the agglomerates. Suction filtered, washed with EtOAc (2x 5mL), and dried under vacuum to generate a brown powder (1.26g). The mother liquor was adsorbed on SiO2 (10g) and on SiO2 (14x 3cm, MeOH / CH2Cl2 1:5), the residue was chromatographed. The eluent was evaporated and toluene (10 mL, to achieve complete removal of MeOH) was added to afford another 0.34 g of hydrazide as an off-white solid; total: 1.60 g (84%). 1 H NMR (DMSO-d6, 400MHz) δ 10.03 (br s, 1H), 9.02 (s, 2H), 4.59 (br s, 2H), 2.66 (s, 3H).
[0493] 5-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-methylpyrimidine
[0494]
[0495] This compound was prepared from N-(2-methylpyrimidine-5-carbonyl)hydrazine in the same manner as described for 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-methylpyridine.
[0496] 2-(Bromomethyl)-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridine
[0497]
[0498] This compound was prepared from 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-methylpyrimidine in the same manner as described for 2-(bromomethyl)-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridine.
[0499] 1-[[5-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl]methyl]-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0500]
[0501] This compound was prepared from 3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide and 2-(bromomethyl)-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidine in the same manner as described for 1-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl]methyl]-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide.
[0502] Compound 31. 1-[[5-[5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl]methyl]-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0503] 2-Methyl-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridine
[0504]
[0505] In a 150 mL round-bottom flask equipped with a stir bar and a reflux condenser (vented to atmosphere) was placed 6-methylnicotinonitrile (2.23 g, 18.9 mmol), EtOH (undenatured, 20 mL) and 50% aqueous hydroxylamine (15.1 M, 1.50 mL, 22.7 mmol, 1.2 equiv.). The mixture was heated to reflux for 23 h. After cooling, TLC (SiO 2 , MeOH / CHCl 3 1:9) showed R f There was one major spot at approximately 0.25. Toluene (20 mL) was added, and the mixture was evaporated to dryness, and the residue was dried under vacuum. The crude amidoxime formed an off-white powder and was used without purification.
[0506] The amidoxime was suspended in CH2Cl2 (180 mL) and transferred to a 500 mL round-bottom flask equipped with a stirring rod, a dropping funnel, and a balloon for removing moisture. Under ice cooling, trifluoroacetic anhydride (11.9 mL, 84.3 mmol, 4.45 equiv.) was added dropwise over 20 min to obtain a clear solution. The cold bath was taken out and the mixture was stirred for 2 h. Triethylamine (19.5 mL, 140 mmol, 7.4 equiv.) was added dropwise over 10 min at ambient temperature, resulting in a mild exotherm. The mixture was stirred at ambient temperature for 3 h. Shortly before this time, TLC (SiO2, EtOAc / hexane 1:4) showed R f The desired product is about 0.4, and R fThe main by-products and several minor by-products of about 0.7 and 0.15 are evaporation generated amber syrup, which is dissolved among the EtOAc and adsorbed on SiO2 (50g). On SiO2 (22x 5cm, EtOAc / hexane 1:5), the residue is chromatographed to obtain a dark orange first distillate, which then generates still impure fractions containing the product, leaving 3.3g of dark orange-red oil and some solids after the evaporation. TLC analysis (SiO2, EtOAc / toluene 1:4) of this material shows that the desired product is the main component, R f The RI was approximately 0.25, accompanied by various non-polar impurities and some baseline material; in particular, one of these byproducts was immediately ahead of the oxadiazole. The oil was applied to a SiO column (30 x 5 cm) and eluted with EtOAc / toluene 1:6. The product-containing fractions (still contaminated with some immediately preceding spots) were evaporated, leaving 2.04 g of oil. This material was finally purified by bulb-to-bulb distillation (approximately 60-65° C. / oil pump) to obtain 1.62 g (37%) of the oxadiazole as a slightly yellowish mobile oil (a large amount of amber crystalline residue was observed). 1 H NMR (400 MHz, CDCl 3 ) δ 9.23 (narrow m, 1H), 8.27 (dd, 1H, J=8.1, 2.3 Hz), 7.34 (d, 1H, J=8.1 Hz), 2.67 (s, 3H). 13 C NMR(100MHz,CDCl3)δ167.45,166.05(q,J C-F =44.6Hz),162.76,148.21,135.09,123.48,118.51,115.88(q,J C-F =273.9Hz),24.72.
[0507] 2-(Bromomethyl)-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridine
[0508]
[0509] In a 100 mL, three-necked flask equipped with a stir bar, heating mantle, stopper, reflux condenser (connected to an Ar balloon), and a septum-filled dropping funnel were placed 2-methyl-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridine (1.60 g, 6.98 mmol), 1,3-dibromo-5,5-dimethylhydantoin (1.10 g, 3.84 mmol, 0.55 equiv.), and fluorobenzene (12 mL). The atmosphere was replaced with Ar. The dropping funnel was charged with a solution of azobis(isobutyronitrile) (AIBN; 0.17 g, 1.05 mmol, 0.15 equiv.) in fluorobenzene (2 mL), of which approximately 10% was added to the reaction mixture. The mixture was heated to reflux, and the remaining AIBN solution was added in small portions over the course of 1.5 h. At this point, most of the temporarily formed Br2 had faded. Reflux was continued for 10 min and the mixture was cooled to ambient temperature. TLC (SiO2, EtOAc / hexane 1:4 or 1:9) showed that in addition to the baseline material, there were three major components, R f about 0.8, 0.6 and 0.35 or R f The fractions were approximately 0.6, 0.35, and 0.2, respectively, corresponding to the dibrominated by-product, the desired monobrominated product, and the starting material. The dark solution was adsorbed onto SiO2 (8 g), and the residue was chromatographed on SiO2 (27 x 4 cm, EtOAc / hexane 1:12). The fractions containing the monobromide were evaporated to yield 0.83 g (38%) of a colorless crystalline solid of good purity. 1 H NMR (400 MHz, CDCl 3 ) δ 9.30 (narrow m, 1H), 8.41 (dd, 1H, J=8.1, 2.1 Hz), 7.64 (d, 1H, J=8.2 Hz), 4.62 (s, 2H).
[0510] 1-[[5-[5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl]methyl]-3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide
[0511]
[0512] In a 100 mL round-bottom flask with a stir bar was placed 3,4-dihydro-1H-benzo[c][1,2]thiazine-2,2-dioxide (181 mg, 988 μmol), 3-[6-(bromomethyl)pyridin-3-yl]-5-(trifluoromethyl)-1,2,4-oxadiazole (320 mg, 1.04 mmol, 1.05 equiv.), finely ground KCO (165 mg, 1.20 mmol, 1.2 equiv.), KI (33 mg, 0.20 mmol, 0.20 equiv.), and anhydrous DMF (3.0 mL). The flask was wrapped in Al foil to shield from light, and the mixture was stirred at ambient temperature for 25.5 h. Water (50 mL) and EtOAc / hexane 1:1 (50 mL) were added, and the phases were separated. The organic phase was washed with water (50 mL). TLC (SiO2, EtOAc / hexane 3:7) showed R f The product is approximately 0.3, indistinguishable from the starting sultam, while the alkylating agent is absent (reference spot, R f When EtOAc / CHCl3 1:9 was used, the f The product was detected at approximately 0.5, while the starting sultam was absent (reference spot, R f The solution was adsorbed onto SiO2 (4 g) and the material was chromatographed on SiO2 (16 x 3 cm, EtOAc / hexane 3:7; tailing). The product-containing fractions were evaporated and dried under vacuum to give the product (392 mg, 97%) as a very pale yellowish glass that gradually solidified upon standing. 1 H NMR (CDCl3, 500 MHz) δ 9.29 (narrow m, 1H), 8.36 (dd, 1H, J = 8.2, 2.1 Hz), 7.71 (d, 1H, J = 8.2 Hz), 7.19 (d, 1H, J = 7.5 Hz), 7.13 (t, 1H, J = 7.7 Hz), 7.02 (t, 1H, J = 7.6 Hz), 6.82 (d, 1H, J = 8.2 Hz), 5.22 (s, 2H), 3.56, 3.50 (AA'BB' multiplet 4H); 13 C NMR(CDCl3,125MHz)δ167.13,166.21(q,J C-F =44.8Hz),161.36,148.39,139.85,136.13,129.72,127.90,123.38,122.28,121.73,120.17,117.78,115.82(q,J C-F =273.9Hz),51.93,45.78,28.22.
[0513] Example 2: Exemplary in vitro activities of the compounds disclosed herein
[0514] Hdac enzyme activity inhibition assay
[0515] By IC 50 The effectiveness or potency of the HDAC6I of the present invention in inhibiting HDAC activity is measured by using a quantitative IC value. 50 The value indicates the concentration of a specific compound required to inhibit 50% of the enzyme activity in vitro. In other words, the IC 50 The IC value is the half-maximal (50%) inhibitory concentration of the compound tested using the specific enzyme of interest (e.g., HDAC). 50 The smaller the value, the more potent the inhibitory effect of the compound, since a lower concentration of compound is required to inhibit enzyme activity by 50%.
[0516] In preferred embodiments, the HDAC6I of the present invention inhibits HDAC enzyme activity by about at least 50%, preferably at least about 75%, at least 90%, at least 95%, or at least 99%.
[0517] The IC values of the compounds of the present invention against HDAC6 and HDAC1 were tested. 50 In some embodiments, compounds of the invention are also tested against HDAC1, 2, 3, 4, 5, 8, 10, and 11. The tested compounds exhibited IC values of about 1 nM to greater than 30 μM relative to HDAC6. 50 values ranged from approximately 91 nM to greater than 30 μM, and the IC relative to HDAC1 50 Therefore, in some embodiments, the HDAC6I of the present invention is a selective HDAC6 inhibitor that produces fewer side effects than non-selective HDAC inhibitor compounds due to its low affinity for other HDAC isozymes (eg, HDAC1).
[0518] In some embodiments, HDACI of the present invention interacts with all histone deacetylases in the cell and reduces its activity. In some preferred embodiments, HDACI of the present invention interacts with less than all histone deacetylases in the cell and reduces its activity. In certain preferred embodiments, HDACI of the present invention interacts with a histone deacetylase (e.g., HDAC6) and reduces its activity, but generally does not interact with other histone deacetylases (e.g., HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11) or reduce its activity. Therefore, the present invention provides HDAC6I for treating a variety of diseases and illnesses in which HDAC6 inhibition can provide a beneficial effect. Preferably, the selectivity of the HDAC6I of the present invention for HDAC6 is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold, at least 2000-fold, at least 3000-fold, and preferably up to about 4000-fold greater than that of other HDAC isozymes. For example, in various embodiments, the HDAC6I of the present invention exhibits an IC of 100-1000 relative to HDAC6. 50 The value ratio is relative to the IC of HDAC1 50 The values were about 350 or about 1000 times lower, i.e., the selectivity ratio (HDAC1IC 50 HDAC6 IC 50 ) is about 350 or about 1000.
[0519] Other analyses also showed that the selectivity of HDAC6I of the present invention for HDAC6 over HDAC1, 2, 3, 4, 5, 8, 10 and 11 was about 1000.
[0520] The IC of the compound of formula (I) relative to HDAC1 and HDAC6 was determined as follows 50 value:
[0521] HDAC1, 2, 4, 5, 6, 7, 8, 9, 10, and 11 were analyzed using isolated recombinant human proteins; the HDAC3 / NcoR2 complex was used for HDAC3 analysis. The substrate for HDAC1, 2, 3, 6, 10, and 11 analysis was a fluorescent peptide from p53 residues 379-382 (RHKKAc); the substrate for HDAC8 was a fluorescent diacyl peptide based on p53 residues 379-382 (RHKAcKAc). Acetyl-lysine (trifluoroacetyl)-AMC substrate was used for HDAC4, 5, 7, and 9 analysis. Compounds were dissolved in DMSO and titrated at a dose of 10 IC 50 The test was performed in 3-fold serial dilution starting from 30 μM. 50The control compound, trichostatin A (TSA), was tested in a 3-fold serial dilution starting from 5 μM. The IC was extracted by curve fitting the dose / response slope. 50 The analysis was performed in duplicate, and the IC 50 The values are the mean of data from two experiments.
[0522] Material
[0523] Human HDAC1 (GenBank Accession No. NM_004964): Full-length, C-terminal GST-tagged, MW = 79.9 kDa, expressed in a baculovirus expression system in Sf9 cells. The enzyme was in 50 mM Tris-HCl (pH 8.0), 138 mM NaCl, 20 mM glutathione, and 10% glycerol and was stable at -80°C for >6 months. Purity was >10% by SDS-PAGE. Specific activity was 20 U / μg, where 1 U = 1 pmol / min. Assay conditions were 25 mM Tris / Cl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.1 mg / mL BSA, 100 μM HDAC substrate, and 13.2 ng / μL HDAC1, incubated at 30°C for 30 min. Human HDAC6 (GenBank Accession No. BC069243): Full-length, N-terminal GST-tagged, MW = 159 kDa, expressed via a baculovirus expression system in Sf9 cells. The enzyme was in 50 mM Tris-HCl (pH 8.0), 138 mM NaCl, 20 mM glutathione, and 10% glycerol and stable at -80°C for >6 months. Purity was >90% by SDS-PAGE. Specific activity was 50 U / μg, where 1 U = 1 pmol / min. Assay conditions were 25 mM Tris / Cl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.1 mg / mL BSA, 30 μM HDAC substrate, and 5 ng / μL HDAC6, incubated at 30°C for 60 min.
[0524] Substrates for HDAC1 and HDAC6: Acetylated peptide substrate for HDAC based on p53 residues 379-382 (Arg-His-Lys-Lys(Ac)), a regulatory acetylation site for p300 and CBP acetyltransferases (lysine 381, 382)1-6, and the best choice for HDAC among a group of substrates patterned on p53, histone H3, and histone H4 acetylation site 7.
[0525] References: Gu, W. et al., Cell 1997, 90, 595; Sakaguchi, K. et al., Genes Dev. 1998, 12, 2831; Liu, L. et al., Mal. Cell. Biol. 1999, 19, 1202; Ito, A. et al., EMBO J., 2001, 20, 1331; Barlev, NA et al., Mal. Cell 2001, 8, 1243; Ito, A. et al., EMBO J. 2002, 21, 6236.
[0526] Reaction buffer: 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mg / mL BSA.
[0527] Analysis conditions
[0528] HDAC1: 75 nM HDAC1 and 50 μM HDAC substrate in reaction buffer and 1% final DMSO. Incubate at 30°C for 2 hours.
[0529] HDAC6: 12.6 nM HDAC6 and 50 μM HDAC substrate in reaction buffer and 1% final DMSO. Incubate at 30°C for 2 hours.
[0530] IC 50 Value Calculation
[0531] All ICs 50 Values were automatically calculated using GraphPad Prism version 5 and the sigmoidal dose-response equation (variable slope):
[0532] Y=Bottom+(Top-Bottom) / (1+10"((LogEC 50 =X)*Hill Slope)), where X is the logarithm of the concentration and Y is the response, with Y starting from the bottom and reaching the top in an S-shape. In most cases, "bottom" is set to 0 and "top" is set to "less than 120%." This is the same as the "four-parameter logistic equation." IC was also plotted using GraphPad Prism. 50 curve, and provide IC 50 value and Hill slope.
[0533] HDAC activity assay: HDAC assays were performed using fluorescently labeled acetylated substrates containing acetylated lysine side chains. Following incubation with HDAC, deacetylation of the substrate sensitizes the substrate, resulting in a fluorophore upon treatment with the detection enzyme in a second step. HDACs 1 and 6 were expressed as full-length fusion proteins. Purified proteins were incubated with 50 μM fluorescently labeled acetylated peptide substrate and test compounds for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA.
[0534] After 2 hours, the reaction was terminated by adding a developer and the development of the fluorescent signal was monitored by EnVision (PerkinElmer) time course measurement, which is related to the amount of deacetylated peptide. HDAC activity was estimated by measuring the slope of the time course of fluorescence intensity. The slope of the no enzyme control (substrate only) was used as background, and the enzyme activity % was calculated using the background of the no inhibitor control (DMSO) minus the slope as 100% activity.
[0535] So far, HDACI has been shown to have a relatively nonspecific inhibitory effect on various HDAC isozymes. Most of the HDACI identified so far mainly suppress HDAC 1, 2, 3 and 8, thereby producing an anti-proliferative phenotype, which can be used for oncology applications, but is useless for many non-oncology applications of HDAC6I. (KB Glaser et al., Biochem.Biophys.Res.Commun.2003,310,529-536.) The potential toxicity caused by suppressing some HDAC isozymes may bring additional difficulties to the clinical development of pan-HDAC (i.e., non-selective HDAC) inhibitors. Because the acetylation-mediated cell effect network is very large, and because suppressing some HDAC isozymes may cause adverse side effects, HDAC isozyme selective inhibitors have greater therapeutic prospects than their non-selective counterparts.
[0536] Several pan-selective compounds have been approved by the FDA, but only for cutaneous T-cell lymphoma and multiple myeloma (Kelly, WK et al., Nat. Clin. Pract. Oncol. 2005, 2, 150-157). Avoiding cytotoxicity through isozyme selectivity will ultimately prove advantageous and may open the door to a variety of other therapeutic areas.
[0537] cell
[0538] The human melanoma cell line WM164 was obtained from the laboratory of Dr. Smalley at Moffitt Cancer Center. Cells were cultured in RPMI 1640 medium (complete medium) supplemented with 10% FBS, penicillin / streptomycin (50 U / mL), L-glutamine (2 mM), and 2-mercaptoethanol (50 mM) and grown at 37°C in a humidified atmosphere of 5% CO2.
[0539] Analysis conditions
[0540] WM164 melanoma cells were plated at 105 cells / well in 12-well plates and allowed to adhere overnight. 50 mM compound stock solution was then added by serial dilution to the indicated concentration in complete culture medium. Cells were incubated for 24 h under humidified conditions (37° C., 5% CO2). Each well was then washed with cold PBS, and the cells were dissolved in a buffer containing 10 mM Tris-HCl (pH 8.0), 10% SDS, 4 mM urea, 100 mM DTT, and 1 x protease inhibitor (Roche). Cells were dissolved on ice for 30 min and then sonicated for 8 min (8 cycles, 30 seconds on / 30 seconds off). Cells were then boiled for 10 min with 6 x gel loading buffer and separated on a 4-15% gradient gel and subsequently transferred to a nitrocellulose membrane. The membrane was blocked with PBS-T containing 5% milk and specific antigens were detected using antibodies against acetyl-H3 and H3 (Cell Signaling) and acetyl-α-tubulin and α-tubulin (Sigma). Bands were detected by scanning the blots using a LI-COR Odyssey imaging system using both 700 and 800 channels.
[0541] Hyperacetylation of α-tubulin without increasing the level of acetylated histones is a hallmark of HDAC6 inhibition. HDAC6 contains two catalytic domains. Its C-terminal domain is the functional domain for synthesis and physiological substrates, while the N-terminal domain does not have enzymatic activity (Zou, H. et al., Biochem.Biophys.Res.Commun., 2006, 341, 45-50). In order to evaluate the activity of the compounds in cells, the ability of some HDAC inhibitors to induce increased levels of tubulin acetylation was evaluated. Figure 1 Western blots are shown. Low micromolar treatment of WM 164 melanoma cells with example compounds resulted in a dose-dependent increase in acetyl α-tubulin levels without a concomitant increase in histone H3 acetylation ( Figure 1), indicating binding to the second enzymatically active catalytic domain. Significant increases in histone H3 acetylation were not observed until concentrations of 1 and 10 μM were used. This is not surprising, as the biochemical IC values of the example compounds against class 1 HDACs (those responsible for histone acetylation) are 50 In the micromolar range, there is a clear preference for activity in cellular contexts corresponding to selective HDAC6 inhibition.
[0542] Cytotoxicity relative to HDAC inhibitory activity
[0543] cell
[0544] The B16-F10-luc murine melanoma cell line was obtained from ATCC and cultured in RPMI 1640 supplemented with 10% FBS, 100 IU / mL penicillin, and 100 mg / mL streptomycin. The SM1 cell line was obtained from the laboratory of Dr. Antoni Ribas at the University of California, Los Angeles. The human melanoma cell line WM164 was obtained from the laboratory of Dr. Smalley at the Moffitt Cancer Center. Cells were cultured in RPMI 1640 medium (complete medium) supplemented with 10% FBS, penicillin / streptomycin (50 U / mL), L-glutamine (2 mM), and 2-mercaptoethanol (50 mM) and grown at 37°C under humidified conditions of 5% CO2.
[0545] Analysis conditions
[0546] Murine melanoma cells were cultured at 5×10 3 / well was plated in a 96-well flat-bottom plate. The next day, the culture medium was changed to a culture medium containing different concentrations of HDAC6I or a matching DMSO vehicle concentration diluted in complete culture medium in triplicate. The cells were incubated at 37 ° C and 5% CO2 for 48 h. According to the manufacturer's instructions, a standard MTS assay (CellTiter96AQueous One, Promega, Madison, WI) was used to quantify the density of living metabolically active cells. In short, 20 μL of reagent was added to each well and incubated at 37 ° C for 3 h. The absorbance at 490 nM was measured spectrophotometrically, and the background was subtracted at 690 nM. Then, all values were standardized and expressed as a percentage of the culture medium control (100%).
[0547] Analysis of compound 1
[0548] Compound 1 exhibited 29 nM potency against hHDAC6 (in duplicate) as shown by DRC, and showed complete selectivity for HDAC1 (DRC) and also over other HDAC isoforms (% inhibition at 10 μM: <20%, see below and raw data) ( Figure 3A ).
[0549] Compound 1 has high kinetic solubility, high permeability, and low efflux. It is characterized by low clearance in human microsomes but higher clearance in mouse microsomes. The free fraction in both mouse and human plasma is high. The compound is chemically stable at pH 7.4 and 2. Although the Clint is higher than the established standard of 50 μl / min / mg protein in Appendix B, we agree to analyze it in mouse PK studies to inform the IV-IV clearance relationship. Figure 3B ).
[0550] The mouse iv PK results of compound 1 indicate that a clearance of 44.9 mL / min / kg was observed, which is about half of the mouse liver blood flow. This medium clearance rate is consistent with the observed microsomal stability. Oral PK studies of compound 1 indicate moderate clearance, moderate volume of distribution, half-life of 2.2 hours and mean residence time of 3.14 hours, as well as low oral bioavailability (14.7%). Shortly after gavage (Tmax = 15 minutes), a mean Cmax value of 456 ng / mL was recorded. The compound has been detected in moderate concentrations in the brain and sciatic nerve, with brain / plasma ratios of 0.8 (at 1 hour) to 1.2 (at 4 hours) and a sciatic nerve / plasma ratio of 0.4 at 1 hour.
[0551] The PK / BBB properties of compound 1, combined with the reported functional activity (0.76 uM), may not be good enough to consider this compound for further in vivo evaluation (at least not in mice).
[0552] Compound 1 may be a promising starting point for optimizing compounds to obtain more potent, selective, and brain-penetrant HDAC6 inhibitors for CNS applications. Additional characterization of compound 1 in other species and optimization of the functional bioactivity and ADME-T / PK properties of future molecules remain to be completed, followed by appropriate efficacy studies to identify preclinical candidates for CNS applications.
[0553] Incorporated by reference
[0554] All publications and patents mentioned herein are hereby incorporated by reference in their entirety to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In the event of a conflict, the present application, including any definitions herein, will control.
[0555] Equivalent solutions
[0556] While specific embodiments of the present invention have been discussed, the above description is illustrative and not restrictive. Many variations of the present invention will become apparent to those skilled in the art upon reading this specification and the following claims. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and this specification, as well as such variations.
Claims
1. A compound having the general formula I: or a pharmaceutically acceptable salt and / or solvate thereof, wherein : represents a single bond or a double bond; in the case of a five-membered ring moiety, there are two double bonds and three single bonds, which are arranged together in such a way as to form a five-membered ring heteroaryl; X and Y are independently carbon or nitrogen, and Z is N or C(F); m = 0, 1 or 2; except when R 1 When deuterium is present, m is an integer ranging from 0 to 4; if at least one of X and Y is carbon, then n=0, 1 or 2; or if both X and Y are nitrogen, then n=0 or 1; The sum of o and p is 0 or 1; R 1 and R 2 are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, -CH 2 OH, -CH 2 CH 2 OH, cyano, -NR a R b 、-CH 2 NR a R b 、-C(O)NR a R b 、-S(O) 2 NR a R b , acetyl, C 1 -C 6 Alkyl, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkyl, F 3 CS-, C 3 -C 6 Cycloalkyl, (C 3 -C 5 Cycloalkyl)-(C 1 -C 3 Alkyl)-, (C 1 -C 3 Alkyl)-(C 3 -C 5 Cycloalkyl)-, (C 3 -C 5 Cycloalkyl)-O-, aryl, aryl-O-, aryl-(C 1 -C 3 Alkyl)-, aryl-(C 1 -C 3 alkoxy)-, heteroaryl, heteroaryl-O-, heteroaryl-(C 1 -C 3 alkyl)-, heteroaryl-(C 1 -C 3 alkoxy)-, 4- to 6-membered heterocyclic group or (4- to 6-membered heterocyclic group)-(C 1 -C 3 alkyl)-; or two R 1 and / or two R 2 attached to adjacent carbon atoms of their respective aromatic rings and joined to form a five- or six-membered carbocyclic or heterocyclic ring; R a and R b independently selected from hydrogen and C 1 -C 6 Alkyl or C 3 -C 6 A group consisting of a cycloalkyl group, or these groups may be joined to form a 3- to 7-membered heterocyclic group; a CR for single key c R d 、C=O、NR e , O or S, or CR for double bond c or N; b in CR for single key c R d or in CR for double bond c , or b in represents a double bond and a is CR c When is N; R c and R d are independently hydrogen, deuterium, fluorine, chlorine, C 1 -C 6 Alkyl or C 3 -C 6 Cycloalkyl, or they are joined together to form a 3- to 6-membered cycloalkyl; R e Selected from the group consisting of: hydrogen, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, aryl, heteroaryl or 4- to 6-membered heterocyclic group; One of c, d and e is oxygen, and the others are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; and R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano.
2. The compound according to claim 1, which has formula Ib in R 1 and R 2 are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, -CH 2 OH, -CH 2 CH 2 OH, cyano, -NR a R b 、-CH 2 NR a R b 、-C(O)NR a R b 、-S(O) 2 NR a R b , acetyl, C 1 -C 6 Alkyl, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkyl, F 3 CS-, C 3 -C 6 Cycloalkyl, (C 3 -C 5 Cycloalkyl)-(C 1 -C 3 Alkyl)-, (C 1 -C 3 Alkyl)-(C 3 -C 5 Cycloalkyl)-, (C 3 -C 5 Cycloalkyl)-O-, aryl, aryl-O-, aryl-(C 1 -C 3 Alkyl)-, aryl-(C 1 -C 3 alkoxy)-, heteroaryl, heteroaryl-O-, heteroaryl-(C 1 -C 3 alkyl)-, heteroaryl-(C 1 -C 3 alkoxy)-, 4- to 6-membered heterocyclic group or (4- to 6-membered heterocyclic group)-(C 1 -C 3 alkyl)-; R a and R b independently selected from hydrogen and C 1 -C 6 Alkyl or C 3 -C 6 These groups may be combined to form a 3- to 7-membered heterocyclic group.
3. The compound according to claim 1, which has formula Ib, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
4. The compound according to claim 1, which has formula Ic Where R 1 and R 2 As defined in claim 1.
5. The compound according to claim 1, which has formula Ic, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
6. The compound according to claim 1, which has formula Id Where R 1 and R 2 As defined in claim 1.
7. The compound according to claim 1, which has formula Id, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
8. The compound according to claim 1, wherein the compound has formula Ie Where R 1 and R 2 As defined in claim 1.
9. The compound according to claim 1, which has the formula Ie, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
10. The compound according to claim 1, wherein the compound has the formula If Where R 1 and R 2 As defined in claim 1.
11. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
12. The compound according to claim 1, which has the formula Ig Where R 1 and R 2 As defined in claim 1.
13. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
14. The compound according to claim 1, wherein the compound has the formula Ih Where R 1 and R 2 As defined in claim 1.
15. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
16. The compound according to claim 1, wherein the compound has formula Ii Where R 1 and R 2 As defined in claim 1.
17. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
18. The compound according to claim 1, wherein the compound has the formula Where R 1 and R 2 As defined in claim 1.
19. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
20. The compound according to claim 1, which has the formula Ik Where R 1 and R 2 As defined in claim 1.
21. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
22. The compound according to claim 1, wherein the compound has the formula IL Where R 1 and R 2 As defined in claim 1, and R 3 is methyl, or two R 3 Together for CH 2 CH 2 .
23. The compound according to claim 1, which has the formula IL, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
24. The compound according to claim 1, wherein the compound has the formula: Where R 1 and R 2 As defined in claim 1.
25. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
26. The compound according to claim 1, wherein the compound has the formula In Where R 1 and R 2 As defined in claim 1, and both R 3 All are methyl, or one R 3 is methyl and the other is H, or both R 3 Together for CH 2 CH 2 or CH 2 CH 2 CH 2 .
27. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
28. The compound according to claim 1, wherein the compound has formula I Where R 1 and R 2 As defined in claim 1, and both R 3 All are methyl, or one R 3 is methyl and the other is H, or both R 3 Together for CH 2 CH 2 or CH 2 CH 2 CH 2 .
29. The compound of claim 1, wherein the compound has formula Io, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
30. The compound according to claim 1, wherein the compound has the formula Ip Where R 1 and R 2 As defined in claim 1.
31. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
32. The compound according to claim 1, wherein the compound has the formula Iq Where R 1 and R 2 As defined in claim 1.
33. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
34. The compound according to claim 1, wherein the compound has the formula Ir Where R 1 and R 2 As defined in claim 1.
35. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
36. The compound according to claim 1, which has the formula Is Where R 1 and R 2 As defined in claim 1.
37. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
38. The compound according to claim 1, which has the formula Where R 1 and R 2 As defined in claim 1.
39. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
40. The compound according to claim 1, wherein the compound has the formula Iu Where R 1 and R 2 As defined in claim 1.
41. The compound of claim 1, wherein the compound has formula Iu, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
42. The compound of claim 1, wherein the compound has Formula Iv Where R 1 and R 2 As defined in claim 1, and R 3 is methyl, or two R 3 Together for CH 2 CH 2 .
43. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
44. The compound of claim 1, wherein the compound has the formula Iw Where R 1 and R 2 As defined in claim 1.
45. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
46. The compound according to claim 1, wherein the compound has the formula Ix Where R 1 and R 2 As defined in claim 1, and both R 3 All are methyl, or one R 3 is methyl and the other is H, or both R 3 Together for CH 2 CH 2 or CH 2 CH 2 CH 2 .
47. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
48. The compound according to claim 1, wherein the compound has the formula Iy Where R 1 and R 2 As defined in claim 1, and both R 3 All are methyl, or one R 3 is methyl and the other is H, or both R 3 Together for CH 2 CH 2 or CH 2 CH 2 CH 2 .
49. The compound of claim 1, wherein the compound has the formula Iy, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
50. The compound according to claim 1, wherein the compound has the formula Iz Where R 1 and R 2 As defined in claim 1.
51. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
52. The compound of claim 1, wherein the compound has formula Iaa Where R 1 and R 2 As defined in claim 1.
53. The compound of claim 1, wherein the compound has formula Iaa, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
54. The compound according to claim 1, wherein the compound has formula Ibb Where R 1 and R 2 As defined in claim 1.
55. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
56. The compound according to claim 1, wherein the compound has the formula Icc Where R 1 and R 2 As defined in claim 1.
57. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
58. The compound according to claim 1, wherein the compound has the formula Idd Where R 1 and R 2 As defined in claim 1.
59. The compound according to claim 1, which has the formula Idd, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
60. The compound according to claim 1, wherein the compound has the formula Iee Where R 1 and R 2 As defined in claim 1.
61. The compound according to claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
62. The compound according to claim 1, wherein the compound has the formula Where R 1 and R 2 As defined in claim 1, and R 3 is methyl, or two R 3 Together for CH 2 CH 2 .
63. The compound according to claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
64. The compound according to claim 1, wherein the compound has the formula Igg Where R 1 and R 2 As defined in claim 1.
65. The compound of claim 1, wherein the compound has the formula Igg, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
66. The compound according to claim 1, wherein the compound has the formula Ihh Where R 1 and R 2 As defined in claim 1, and both R 3 All are methyl, or one R 3 is methyl and the other is H, or both R 3 Together for CH 2 CH 2 or CH 2 CH 2 CH 2 .
67. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
68. The compound according to claim 1, wherein the compound has formula Iii Where R 1 and R 2 As defined in claim 1, and both R 3 All are methyl, or one R 3 is methyl and the other is H, or both R 3 Together for CH 2 CH 2 or CH 2 CH 2 CH 2 .
69. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
70. The compound according to claim 1, wherein the compound has the formula Where R 1 and R 2 As defined in claim 1.
71. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
72. The compound of claim 1, wherein the compound has the formula Ikk Where R 1 and R 2 As defined in claim 1.
73. The compound of claim 1, wherein R 1 and R 2 Independently selected from H, D, Cl and F.
74. The compound according to claim 1, wherein the compound has the formula ILL in represents a single bond or a double bond; of the five bonds so marked, two are double bonds and three are single bonds, which are arranged together in such a way as to form a five-membered ring heteroaryl group; One of c, d and e is oxygen, and the others are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano; And R 1 and R 2 As defined in claim 1.
75. The compound of claim 1, wherein the compound has the formula ILL, wherein R 1 and R 2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
76. The compound according to claim 1, wherein the compound has the formula Imm in represents a single bond or a double bond; of the five bonds so marked, two are double bonds and three are single bonds, which are arranged together in such a way as to form a five-membered ring heteroaryl group; One of c, d and e is oxygen, and the others are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano; And R 1 and R 2 As defined in claim 1.
77. The compound of claim 1, wherein R 1 and R 2 are independently selected from H, D, Cl and F, c and e are nitrogen, and d is oxygen.
78. The compound according to claim 1, wherein the compound has the formula: in represents a single bond or a double bond; of the five bonds so marked, two are double bonds and three are single bonds, which are arranged together in such a way as to form a five-membered ring heteroaryl group; One of c, d and e is oxygen, and the others are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano; And R 1 and R 2 As defined in claim 1.
79. The compound of claim 1, wherein R 1 and R 2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
80. The compound of claim 1, wherein the compound has the formula in represents a single bond or a double bond; of the five bonds so marked, two are double bonds and three are single bonds, which are arranged together in such a way as to form a five-membered ring heteroaryl group; One of c, d and e is oxygen, and the others are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano; And R 1 and R 2 As defined in claim 1.
81. The compound of claim 1, wherein R 1 and R 2 are independently selected from H, D, Cl and F, c and e are nitrogen, and d is oxygen.
82. The compound according to claim 1, wherein the compound has the formula Ipp in represents a single bond or a double bond; of the five bonds so marked, two are double bonds and three are single bonds, which are arranged together in such a way as to form a five-membered ring heteroaryl group; One of c, d and e is oxygen, and the others are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano; And R 1 and R 2 As defined in claim 1.
83. The compound according to claim 1, which has the formula Ipp, wherein R 1 and R 2 are independently selected from H, D, Cl and F, c and d are nitrogen, and e is oxygen.
84. The compound of claim 1, wherein the compound has the formula Iqq in One of c, d and e is oxygen, and the others are nitrogen; or c is C(R f ), one of d and e is oxygen, and the other is nitrogen; R f is hydrogen, deuterium, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl or cyano; And R 1 and R 2 As defined in claim 1.
85. The compound of claim 1, wherein R 1 and R 2 are independently selected from H, D, Cl and F, c and e are nitrogen, and d is oxygen.
86. The compound of claim 1, wherein the compound is selected from the group consisting of: or pharmaceutically acceptable salts thereof.
87. A composition comprising (a) a compound as described in claims 1-86; (b) a second therapeutic agent useful for treating a disease or condition in which HDAC inhibition would provide a benefit; and (c) optionally an excipient and / or a pharmaceutically acceptable carrier.
88. The composition of claim 87, wherein the second therapeutic agent comprises a chemotherapeutic agent useful for treating cancer.
89. A pharmaceutical composition comprising a compound as described in claims 1-86 and a pharmaceutically acceptable carrier or vehicle.
90. A method of treating a disease or condition in which HDAC inhibition would provide a benefit, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claims 1-86.
91. The method of claim 90, wherein the HDAC is HDAC6.
92. The method of claim 90, further comprising administering a therapeutically effective amount of a second therapeutic agent useful for treating the disease or disorder.
93. The method of claim 92, wherein the compound of claims 1-86 and the second therapeutic agent are administered simultaneously.
94. The method of claim 92, wherein the compound of claims 1-86 and the second therapeutic agent are administered separately.
95. The method of claim 90, wherein the disease or disorder is cancer.
96. The method of claim 92, wherein the disease is cancer and the second therapeutic agent is one or more of a chemotherapeutic agent, radiation, and immunotherapy.
97. The method of claim 96, wherein the second therapeutic agent comprises radiation, and the radiation is optionally administered in conjunction with a radiosensitizer and / or a therapeutic agent.
98. The method of claim 90, wherein the disease or disorder is a neurological disease, a neurodegenerative disorder, a peripheral neuropathy, or a traumatic brain injury.
99. The method of claim 90, wherein the disease or disorder is stroke.
100. The method of claim 90, wherein the disease or disorder is an inflammatory or autoimmune disease.
101. The method of claim 100, further comprising administering a therapeutically effective amount of a second therapeutic agent useful for treating the autoimmune disease or the inflammation.
102. A method of increasing the sensitivity of cancer cells to the cytotoxic effects of radiation therapy and / or chemotherapy, the method comprising contacting the cells with a compound of claims 1-86 in an amount sufficient to increase the sensitivity of the cells to the radiation therapy and / or chemotherapy.
